WO2014167530A1 - Cannabinoid compounds - Google Patents
Cannabinoid compounds Download PDFInfo
- Publication number
- WO2014167530A1 WO2014167530A1 PCT/IB2014/060636 IB2014060636W WO2014167530A1 WO 2014167530 A1 WO2014167530 A1 WO 2014167530A1 IB 2014060636 W IB2014060636 W IB 2014060636W WO 2014167530 A1 WO2014167530 A1 WO 2014167530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- compound
- nrr
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 318
- 239000003557 cannabinoid Substances 0.000 title abstract description 20
- 229930003827 cannabinoid Natural products 0.000 title abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 230000036407 pain Effects 0.000 claims abstract description 16
- 206010027940 Mood altered Diseases 0.000 claims abstract description 11
- 206010047700 Vomiting Diseases 0.000 claims abstract description 11
- 230000007510 mood change Effects 0.000 claims abstract description 11
- 206010028813 Nausea Diseases 0.000 claims abstract description 10
- 230000036528 appetite Effects 0.000 claims abstract description 10
- 235000019789 appetite Nutrition 0.000 claims abstract description 10
- 230000008693 nausea Effects 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- 230000002743 euphoric effect Effects 0.000 claims abstract description 7
- -1 Ci-C8 alkyl Chemical group 0.000 claims description 354
- 125000003118 aryl group Chemical group 0.000 claims description 333
- 125000000217 alkyl group Chemical group 0.000 claims description 247
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 203
- 125000000623 heterocyclic group Chemical group 0.000 claims description 182
- 229910052739 hydrogen Inorganic materials 0.000 claims description 122
- 239000001257 hydrogen Substances 0.000 claims description 121
- 150000003839 salts Chemical class 0.000 claims description 118
- 125000005843 halogen group Chemical group 0.000 claims description 109
- 239000000651 prodrug Substances 0.000 claims description 107
- 229940002612 prodrug Drugs 0.000 claims description 107
- 125000000304 alkynyl group Chemical group 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 87
- 229910052760 oxygen Inorganic materials 0.000 claims description 87
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 84
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 74
- 125000003342 alkenyl group Chemical group 0.000 claims description 72
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 67
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 67
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 66
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 62
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 60
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 60
- 125000003106 haloaryl group Chemical group 0.000 claims description 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 50
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 125000001246 bromo group Chemical group Br* 0.000 claims description 42
- 125000001153 fluoro group Chemical group F* 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 40
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 37
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000001188 haloalkyl group Chemical group 0.000 claims description 31
- 229940076279 serotonin Drugs 0.000 claims description 29
- 108091006146 Channels Proteins 0.000 claims description 26
- 125000004407 fluoroaryl group Chemical group 0.000 claims description 24
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 20
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical group S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 18
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 14
- 229910006069 SO3H Inorganic materials 0.000 claims description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 14
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 14
- 230000001800 adrenalinergic effect Effects 0.000 claims description 13
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 12
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 10
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 claims description 10
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 claims description 10
- 229960005305 adenosine Drugs 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 8
- 108010012236 Chemokines Proteins 0.000 claims description 7
- 102000019034 Chemokines Human genes 0.000 claims description 7
- 229960003638 dopamine Drugs 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229960001340 histamine Drugs 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 102000003797 Neuropeptides Human genes 0.000 claims description 6
- 108090000189 Neuropeptides Proteins 0.000 claims description 6
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 5
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims description 5
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 5
- 101150037782 GAL2 gene Proteins 0.000 claims description 5
- 101800002068 Galanin Proteins 0.000 claims description 5
- 102100021735 Galectin-2 Human genes 0.000 claims description 5
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 5
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 5
- 101800001814 Neurotensin Proteins 0.000 claims description 5
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims description 5
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 5
- 229960003987 melatonin Drugs 0.000 claims description 5
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 5
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 5
- 230000002040 relaxant effect Effects 0.000 claims description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 4
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 4
- 108010064733 Angiotensins Proteins 0.000 claims description 4
- 102000015427 Angiotensins Human genes 0.000 claims description 4
- 101800004538 Bradykinin Proteins 0.000 claims description 4
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 4
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 4
- 102100021942 C-C motif chemokine 28 Human genes 0.000 claims description 4
- 101800001982 Cholecystokinin Proteins 0.000 claims description 4
- 102100025841 Cholecystokinin Human genes 0.000 claims description 4
- 102000002045 Endothelin Human genes 0.000 claims description 4
- 108050009340 Endothelin Proteins 0.000 claims description 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 4
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 claims description 4
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 102000003141 Tachykinin Human genes 0.000 claims description 4
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 4
- 108010004977 Vasopressins Proteins 0.000 claims description 4
- 102000002852 Vasopressins Human genes 0.000 claims description 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 4
- 229940107137 cholecystokinin Drugs 0.000 claims description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 108060008037 tachykinin Proteins 0.000 claims description 4
- 229960003726 vasopressin Drugs 0.000 claims description 4
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 claims description 3
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- PCNRQYHSJVEIGH-ASTDGNLGSA-M sodium;5-benzo[e]benzotriazol-2-yl-2-[(e)-2-phenylethenyl]benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC(N2N=C3C4=CC=CC=C4C=CC3=N2)=CC=C1\C=C\C1=CC=CC=C1 PCNRQYHSJVEIGH-ASTDGNLGSA-M 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 102400000967 Bradykinin Human genes 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 102000050267 Neurotensin Human genes 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 148
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 146
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 84
- HINCNLQQLQFMRD-UHFFFAOYSA-N 1-(oxan-4-ylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)NC(=O)C(C1=CC=CC=C11)=NN1CC1CCOCC1 HINCNLQQLQFMRD-UHFFFAOYSA-N 0.000 description 76
- LCBASRYREGWIJT-UHFFFAOYSA-N 1-pentyl-n-(2-phenylpropan-2-yl)indazole-3-carboxamide Chemical compound C12=CC=CC=C2N(CCCCC)N=C1C(=O)NC(C)(C)C1=CC=CC=C1 LCBASRYREGWIJT-UHFFFAOYSA-N 0.000 description 62
- ABBDMPBQHOHMJZ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-N-(2-phenylpropan-2-yl)indazole-3-carboxamide Chemical compound CC(C)(NC(=O)c1nn(Cc2ccc(F)cc2)c2ccccc12)c1ccccc1 ABBDMPBQHOHMJZ-UHFFFAOYSA-N 0.000 description 54
- 238000005481 NMR spectroscopy Methods 0.000 description 52
- 238000000034 method Methods 0.000 description 42
- 230000000694 effects Effects 0.000 description 37
- 239000004480 active ingredient Substances 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 239000000556 agonist Substances 0.000 description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- 239000002287 radioligand Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000007788 liquid Substances 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 239000002585 base Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 229940016409 methylsulfonylmethane Drugs 0.000 description 18
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 239000002775 capsule Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229960004063 propylene glycol Drugs 0.000 description 12
- 235000013772 propylene glycol Nutrition 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 238000007429 general method Methods 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000007897 gelcap Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940093499 ethyl acetate Drugs 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 9
- 238000010626 work up procedure Methods 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- XSHGVIPHMOTDCS-UHFFFAOYSA-N 1-(5-fluoropentyl)-n-(2-phenylpropan-2-yl)indazole-3-carboxamide Chemical compound N=1N(CCCCCF)C2=CC=CC=C2C=1C(=O)NC(C)(C)C1=CC=CC=C1 XSHGVIPHMOTDCS-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 6
- 108050007331 Cannabinoid receptor Proteins 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940065144 cannabinoids Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000006735 (C1-C20) heteroalkyl group Chemical group 0.000 description 5
- RCXFMWJQOYCIQU-UHFFFAOYSA-N 1-pentyl-n-(2-phenylpropan-2-yl)indole-3-carboxamide Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)NC(C)(C)C1=CC=CC=C1 RCXFMWJQOYCIQU-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 5
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 4
- 125000006738 (C6-C20) heteroaryl group Chemical group 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000218236 Cannabis Species 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 102400001370 Galanin Human genes 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PRXGMEURJXGKOP-UHFFFAOYSA-N NP(N)=O Chemical class NP(N)=O PRXGMEURJXGKOP-UHFFFAOYSA-N 0.000 description 4
- 102400001103 Neurotensin Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003571 electronic cigarette Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 0 *C(*)(*)*c1b[n](*)c2c1c(*)c(*)c(*)c2* Chemical compound *C(*)(*)*c1b[n](*)c2c1c(*)c(*)c(*)c2* 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 3
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 239000004150 EU approved colour Substances 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100035792 Kininogen-1 Human genes 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 101710151321 Melanostatin Proteins 0.000 description 3
- 102100029698 Metallothionein-1A Human genes 0.000 description 3
- COOPWWXIRLDJCP-UHFFFAOYSA-N N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide Chemical compound CC(C)(NC(=O)c1n[nH]c2ccccc12)c1ccccc1 COOPWWXIRLDJCP-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 240000000143 Turnera diffusa Species 0.000 description 3
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000007701 flash-distillation Methods 0.000 description 3
- 235000019264 food flavour enhancer Nutrition 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000004952 turnera diffusa Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101100167640 Glycine max CLV1B gene Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010049816 Muscle tightness Diseases 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 2
- 101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 2
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 125000000068 chlorophenyl group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- VIRRLEDAYYYTOD-YHEOSNBFSA-N colforsin daropate hydrochloride Chemical compound Cl.O[C@H]([C@@]12C)CCC(C)(C)[C@@H]1[C@H](OC(=O)CCN(C)C)[C@H](OC(C)=O)[C@]1(C)[C@]2(O)C(=O)C[C@](C)(C=C)O1 VIRRLEDAYYYTOD-YHEOSNBFSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940126513 cyclase activator Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 235000002864 food coloring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 125000005500 uronium group Chemical group 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 1
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- JGTSOWOPISVAHG-UHFFFAOYSA-N 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide Chemical compound C(#N)CCCCN1N=C(C2=CC=CC=C12)C(=O)NC(C)(C)C1=CC=CC=C1 JGTSOWOPISVAHG-UHFFFAOYSA-N 0.000 description 1
- RGSVXQJPSWZXOP-UHFFFAOYSA-N 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Chemical compound C1CCCCN1C1(C=2SC3=CC=CC=C3C=2)CCCCC1 RGSVXQJPSWZXOP-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHNDVXVERSIHRZ-UHFFFAOYSA-N 1-pentylindazole-3-carboxylic acid Chemical compound C1=CC=C2N(CCCCC)N=C(C(O)=O)C2=C1 NHNDVXVERSIHRZ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- MQNYRKWJSMQECI-QFIPXVFZSA-N 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(C)C=1C1=CC=CC=C1 MQNYRKWJSMQECI-QFIPXVFZSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WWJHRSCUAQPFQO-UHFFFAOYSA-M 4-DAMP methiodide Chemical compound [I-].C1C[N+](C)(C)CCC1OC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 WWJHRSCUAQPFQO-UHFFFAOYSA-M 0.000 description 1
- VTZVGBZAMQCGPU-UHFFFAOYSA-N 4-amino-5-[2-[[1-[[1-[[6-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[4-amino-1-[2-[[2-[[1-[[1-[[1-[[1-[[6-amino-1-[[1-[2-[[1-[[1-[[1-[[1-[[4-amino-1-[[5-amino-1-[[6-amino-1-[[6-amino-1-[[6-amino-1-[[5-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[2-[[1-[[2-[[2-[[4-amino-1-[[1-[[4-amino-1-[[1-[[1-[[6-amino-1-[[1-[[1-[[1-[[1-[[1-[[5-carbamimidamido-1-[[5-carbamimidamido-1-[[1-[[1-[[1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound CCC(C)C(C(=O)NCC(=O)O)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CS)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)C(CS)NC(=O)CNC(=O)C(CO)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC(=O)O)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)C(CS)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C)NC(=O)C8CCCN8C(=O)C(C(C)CC)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CS)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C1CCCN1C(=O)C(CC(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(CCC(=O)O)N VTZVGBZAMQCGPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101710126338 Apamin Proteins 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- GANMWOAMCYQVCX-UHFFFAOYSA-N CC(C)(C=C)NC(c1c[n](CCCCCF)c2ccccc12)=O Chemical compound CC(C)(C=C)NC(c1c[n](CCCCCF)c2ccccc12)=O GANMWOAMCYQVCX-UHFFFAOYSA-N 0.000 description 1
- BMAQILNKSFTDRA-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1n[n](CC2CCCCC2)c2c1[I]=CC=C2)=O Chemical compound CC(C)(c1ccccc1)NC(c1n[n](CC2CCCCC2)c2c1[I]=CC=C2)=O BMAQILNKSFTDRA-UHFFFAOYSA-N 0.000 description 1
- MTMVUBQQIGZSQB-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1n[n](CCN2CCCCC2)c2ccccc12)=O Chemical compound CC(C)(c1ccccc1)NC(c1n[n](CCN2CCCCC2)c2ccccc12)=O MTMVUBQQIGZSQB-UHFFFAOYSA-N 0.000 description 1
- FLPXJUOXCBVRKW-UHFFFAOYSA-N CCCCC[n]1c2ccccc2c(C(NC(C)(C)C#C)=O)c1 Chemical compound CCCCC[n]1c2ccccc2c(C(NC(C)(C)C#C)=O)c1 FLPXJUOXCBVRKW-UHFFFAOYSA-N 0.000 description 1
- ZTOKQAQJTXECFI-UHFFFAOYSA-N CCCCC[n]1c2ccccc2c(S(NC(C)(C)c2ccccc2)(=O)=O)c1 Chemical compound CCCCC[n]1c2ccccc2c(S(NC(C)(C)c2ccccc2)(=O)=O)c1 ZTOKQAQJTXECFI-UHFFFAOYSA-N 0.000 description 1
- MUDPDKBVDRXYTE-UHFFFAOYSA-N CCCCC[n]1nc(COC(C)(C)c2ccccc2)c2ccccc12 Chemical compound CCCCC[n]1nc(COC(C)(C)c2ccccc2)c2ccccc12 MUDPDKBVDRXYTE-UHFFFAOYSA-N 0.000 description 1
- 241001077823 Calea Species 0.000 description 1
- 229940123549 Cannabinoid CB1 receptor agonist Drugs 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 1
- MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 1
- VFIDUCMKNJIJTO-BBRMVZONSA-N ICI 118551 Chemical compound CC(C)N[C@@H](C)[C@@H](O)COC1=CC=C(C)C2=C1CCC2 VFIDUCMKNJIJTO-BBRMVZONSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000219644 Leonotis ocymifolia Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 description 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical class NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 description 1
- 108700003003 NPC 567 Proteins 0.000 description 1
- RBIXVHPHNGXTCI-QJTYZATASA-N NPC-567 Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 RBIXVHPHNGXTCI-QJTYZATASA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102400001111 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- 102100028646 Nociceptin receptor Human genes 0.000 description 1
- 240000009085 Nymphaea caerulea Species 0.000 description 1
- 235000002195 Nymphaea caerulea Nutrition 0.000 description 1
- 235000016428 Nymphaea stellata Nutrition 0.000 description 1
- KUKBLJOFEXKBIG-UHFFFAOYSA-N O=C(c1c[n](CC2CCOCC2)c2ccccc12)NC1(CCCC1)c1ccccc1 Chemical compound O=C(c1c[n](CC2CCOCC2)c2ccccc12)NC1(CCCC1)c1ccccc1 KUKBLJOFEXKBIG-UHFFFAOYSA-N 0.000 description 1
- AWZPHMZWUMYXPM-UHFFFAOYSA-N O=C(c1n[n](CCCCCF)c2ccccc12)NC1(CC1)c1ccccc1 Chemical compound O=C(c1n[n](CCCCCF)c2ccccc12)NC1(CC1)c1ccccc1 AWZPHMZWUMYXPM-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 240000002690 Passiflora mixta Species 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- PIMZUZSSNYHVCU-OMKDEKJRSA-N Picrotoxinin Natural products O=C1O[C@@H]2[C@@H](C(=C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@H]2C1 PIMZUZSSNYHVCU-OMKDEKJRSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010038584 Repetitive strain injury Diseases 0.000 description 1
- 235000011771 Salvia divinorum Nutrition 0.000 description 1
- 241001136613 Salvia divinorum Species 0.000 description 1
- 108010083387 Saralasin Proteins 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010049514 Traumatic fracture Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- RPMBYDYUVKEZJA-UHFFFAOYSA-N methoctramine Chemical compound COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC1=CC=CC=C1OC RPMBYDYUVKEZJA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- DCBKCZSYJRZBDB-UHFFFAOYSA-N oxan-4-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CCOCC1 DCBKCZSYJRZBDB-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- PIMZUZSSNYHVCU-YKWPQBAZSA-N picrotoxinin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2 PIMZUZSSNYHVCU-YKWPQBAZSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 1
- 229960004785 saralasin Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- HDDNYFLPWFSBLN-ZSHCYNCHSA-N tropanyl 3,5-dimethylbenzoate Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(C)=CC(C)=C1 HDDNYFLPWFSBLN-ZSHCYNCHSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates generally to cannabinoid compounds and compositions, more particularly new indole and indazole cannabinoids and compositions, and applications of these.
- Cannabinoids are a class of diverse chemical compounds that activate cannabinoid receptors.
- the broader definition of the term “cannabinoids” refers to a group of compounds that are structurally related to tetrahydrocannabinol (THC) or that bind to cannabinoid receptors.
- THC tetrahydrocannabinol
- Such compounds include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (produced chemically by humans).
- the most notable cannabinoid is delta-9 THC, the primary psychoactive compound of cannabis.
- Delta-9 THC the principle active component of cannabis, is a member of a large family of cannabinoid compounds that mediate physiological and psychotropic effects including immunosuppression, analgesia, inflammation, emesis, and intraocular pressure.
- Cannabinoids work through selective binding to G-protein coupled cannabinoid receptors.
- Two types of cannabinoid receptors have been cloned: CBi and CB 2 .
- the CBi receptor is found mainly on cells of the central nervous system, while the CB 2 receptor is found mainly on cells of the peripheral nervous system including cells comprising the immune system, such as lymphoid cells.
- Cannabinoid compounds that bind to CBi and/or CB 2 receptors, such as delta-9 THC, are known to have gastrointestinal, cardiovascular, and/or central nervous system activity. Such compounds may, therefore, offer therapeutic approaches to a variety of diseases or conditions.
- the present invention provides a compound of formula I,
- B is selected from CH or N;
- Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted; R2-R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO 3 H, NRi 2a Ri2b, S0 2 NR 12a
- R 6a and R 6 b are each independently selected from Ci-C 8 alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
- R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- Ri 2a and Ri3 ⁇ 4 are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
- the present invention provides a compound of formula I,
- B is selected from CH or N;
- Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
- R2-R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi2aRi2b, CONRi 2a Ri2b, halo, Ci-Cs alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Q- Cs alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- R 6a and R 6b are each independently selected from Ci-Cs alkyl or R6 a and R 6b together form a C3-C6 cycloalkyl ring;
- R 6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C 2 -Cs haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- Ri2a and Ri 2 b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
- the invention provides the present invention provides a compound of formula I,
- R 6a and R 6b together form 3 to 7 membered heterocycle
- Y, B, Ri, R2-R5, and R 6c are as defined in first aspect above;
- the invention provides the present invention provides a compound of formula I,
- R 6c is cyano
- Y, B, Ri, R2-R5, R 6a and R 6b are as defined in the first aspect above;
- the present invention provides a compound of formula la,
- Yi is selected from O, S, or S0 2 ;
- Y 2 is selected from CH 2 , O, or NH;
- B is selected from CH or N;
- Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Q-Q alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
- R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or 3 to 7 membered heterocyclyl ring;
- Ri2a and R 12b are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -Cg alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
- Yi is selected from O, S, or S0 2 ;
- Y 2 is selected from CH 2 , O, or NH;
- B is selected from CH or N;
- Ri is selected from CONR 12a Ri 2b , COR 12a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
- R 2 -R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring; and Ri2a and Ri 2b are each independently selected from hydrogen, Ci-Cg alkyl, C 2 -C8 alkenyl, C 2 -Cs alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
- the invention provides the present invention provides a compound of formula la,
- R 6a and R 6b together form 3 to 7 membered heterocycle
- Yi, Y 2 , B, Ri, R 2 -R5 and R7-R11 are as defined in fifth aspect above;
- the invention in another aspect, relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
- the invention in another aspect, relates to a compound of the invention for use in treating pain in a subject.
- the invention related to a compound of the invention for use in treating nausea and/or emesis in a subject.
- the invention relates to a compound of the invention for use in stimulating appetite in a subject.
- the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
- the invention in another aspect, relates to a compound of the invention for use in relaxing a subject.
- the invention in another aspect, relates to a compound of the invention for use in inducing a positive mood change in a subject.
- Figure 1 shows a 1H NMR scan for the compound SGT-42.
- Figure 2 shows a 13C NMR scan for the compound SGT-42. 5.
- therapeutically effective amount means the amount of an active compound, or a material, composition, composition, or dosage form comprising an active compound, which is effective for producing some desired therapeutic or prophylactic effect, commensurate with a reasonable benefit/risk ratio.
- Therapeutically effective amounts can be determined using routine optimisation techniques well known in the art.
- pharmaceutically acceptable refers to compounds of the invention, ingredients, materials and the like, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of a human without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier must also be “acceptable” in the sense of being compatible with the other ingredients of the composition.
- treatment and related terms, such as “treating” and “treat” as used herein, in the context of treating a condition, relates generally to treatment of a human, in which some desired therapeutic effect is achieved.
- the therapeutic effect may, for example, be the inhibition of progress of the condition, including a reduction in the rate of progress; a halt in the rate of progress of the condition; amelioration of the condition; and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis
- Treatment also includes combination treatments and therapies, in which two or more treatments or therapies are used, for example, sequentially or simultaneously, in combination.
- a therapeutically effective amount of a compound of the invention could be combined with or used in conjunction with a known cannabinoid compound.
- alkyl means a saturated hydrocarbon radical containing normal, secondary, or tertiary carbon atoms.
- suitable alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl- 1-propyl (i- Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2
- alkenyl means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one double bond.
- alkynyl means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one triple bond.
- alkynyl groups include, but are not limited to, acetylenic (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH), and the like.
- cycloalkyl means a hydrocarbon radical containing a saturated ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
- Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
- Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
- aryl means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
- an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
- Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
- alkoxy means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
- suitable alkoxy groups include, but are not limited to, methoxy (-O-CH 3 or -OMe), ethoxy
- halo as used herein means iodo, bromo, chloro, or fluoro.
- haloalkyl means an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halo group.
- suitable haloalkyl groups include, but are not limited to, -(CH 2 ) n F, -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 , and the like.
- haloalkenyl and “haloalkynyl” have analogous meanings.
- optionally substituted in reference to a particular moiety of the compound of the invention (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents.
- substituted in reference to alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl means alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
- a C1-4 substituted alkyl refers to a C1-4 alkyl, which can be substituted with groups having more than the, e.g., 4 carbon atoms.
- prodrug refers to any compound that when administered to a biological system generates the compound of the invention, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalysed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
- a prodrug is thus a covalently modified analogue or latent form of a therapeutically active compound.
- heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
- the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH 3 , etc.), an amine (e.g., -NHCH 3 , -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH 3 ).
- a heteroatom e.g., O, N, or S
- the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH 3 , etc.), an amine (e.g., -NHCH 3 , -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH 3 ).
- the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH2CH2-O-CH3, etc.), an alkyl amine (e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.), or a thioalkyl ether (e.g.,-CH 2 -S-CH 3 ).
- an alkyl ether e.g., -CH2CH2-O-CH3, etc.
- an alkyl amine e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.
- a thioalkyl ether e.g.,-CH 2 -S-CH 3
- the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH 2 CH 2 -OH), an aminoalkyl group (e.g., -CH 2 NH 2 ), or an alkyl thiol group (e.g., -CH 2 CH 2 -SH).
- a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
- a Ci-C 6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
- heterocycle or “heterocyclyl” as used herein include by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern
- heterocyclic Chemistry W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Chem. Soc. (1960) 82:5566.
- the terms “heterocycle” and “heterocyclyl” include saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings ⁇ i.e., heteroaromatic rings).
- heterocycle and heterocyclyl also include substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
- substituted heterocycles include, but are not limited to, 4,4-difluoro-l-piperidinyl and N-methyl-2-piperidinyl.
- heterocycle or “heterocyclyl” employed alone or in combination with other terms means, unless otherwise stated, a saturated or unsaturated non-aromatic monocyclic heterocyclyl ring or a bicyclic heterocyclyl ring.
- Monocyclic heterocyclyl rings include monovalent 3-, 4-, 5-, 6-, or 7-membered rings containing one or more heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur in the ring.
- Monocyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the ring. Examples of monocyclic
- heterocyclyl groups include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny
- Bicyclic heterocyclyl rings include monovalent monocyclic heterocyclyl rings fused to phenyl rings, cycloalkyl rings, or other monocyclic heterocyclyl rings. Bicyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the rings.
- bicyclic heterocyclyl groups include, but are not limited to, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3- dihydro- 1 -benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3-dihydro-lH-indolyl, and 1,2,3,4- tetrahydroquinolinyl.
- the heterocyclyl is monocyclic.
- Heteroaryl refers to an aromatic heterocyclyl.
- suitable heteroatoms which can be included in the aromatic ring include oxygen, sulphur, and nitrogen.
- heteroaryl rings include pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
- carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
- tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
- carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.
- halogenating agent includes phosphorous oxychloride, thionyl chloride, oxalyl chloride, phosphorous trichloride, phosphorous pentachloride, and diphosgene.
- halogenated solvent includes chloroform, dichloromethane, and carbon tetrachloride.
- chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are
- stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- Diastereomer refers to a stereoisomer with two or more centres of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
- Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- the invention provides cannabinoid compounds that have a range of therapeutic activities including analgesic, anti-inflammatory, and anti-emetic.
- the compounds of the invention also have psychotropic effects so can be used as relaxants to induce positive mood change.
- the present invention provides a compound of formula I,
- B is selected from CH or N;
- Ri is selected from CONRi 2a Ri2b, CORi 2a , COORi 2a , C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
- R 2 -R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi 2a Ri2b, CONRi2aRi 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Q- Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring;
- R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -C 8 haloalkenyl, C 2 -Cg haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- Ri 2a and Ri3 ⁇ 4 are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
- the present invention provides a compound of formula I,
- B is selected from CH or N;
- R 6a and R 6 b are each independently selected from Ci-C 8 alkyl or R6 a and R 6 b together form a C 3 -C 6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
- each X is independently halo
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C6-Ci 2 fluoroaryl, C 6 -Ci2 aryl Ci- Cg alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
- the invention provides the present invention provides a compound of formula I,
- R 6a and R 6 b together form 3 to 7 membered heterocycle
- Y, B, Ri, R 2 -R5, and R 6c are as defined in preceding aspect
- the invention provides the present invention provides a compound of formula I,
- R 6c is cyano
- Y, B, Ri, and R2-R5 are as defined in the preceding aspect.
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring
- the present invention provides a compound of formula I,
- B is selected from CH or N;
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring;
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- Ri2 a and Ri2b are each independently selected from hydrogen, Ci-C 8 alkyl, or C6-C12 aryl.
- Ri2 a and Ri2b are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
- each X is independently halo
- each R is independently H, Ci-Cio alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- C 8 alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle.
- each X is independently halo
- each R is independently H, Ci-Cio alkyl, C 6 -Ci 2 aryl, C6-C 12 fluoroaryl, C 6 -Ci 2 aryl Cp
- each X is independently halo
- each R is independently H, C 1 -C 10 alkyl, C 6 -Ci 2 aryl, C6-C 12 fluoroaryl, C 6 -Ci 2 aryl Ci- Cg alkyl, C3-C 12 cycloalkyl, bridged C 6 -Ci 2 cycloalkyl, halo or perhalo substituted C 3 -C 12 cycloalkyl, or a C 3 -C 12 heterocycle.
- each X is independently halo
- each R is independently H, C 1 -C 10 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- Cg alkyl, C 3 -C 12 cycloalkyl, bridged C 6 -Ci 2 cycloalkyl, perhalo substituted C 3 -C 12 cycloalkyl, or a C 3 -C 12 heterocycle.
- each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
- Ri is selected from C1-C6 alkyl, Ci-C 6 bromoalkyl, C1-C6 fluoroalkyl, C 6 -Ci2 aryl, C3-C12 cycloalkyl, Ci-C 6 alkylene-3,3-difluoro- l-cyclohexyl, Ci-C 6 alkylene-p- fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2-bicyclo[2.2.1]heptanyl, or Ci-C 6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro.
- Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl.
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene cyclohexyl, methylene-3,3-difluoro- l-cyclohexyl, methylene-p-fluoro-phenyl, methylene- adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2- bicyclo[2.2.1]heptanyl, and methylene-4-tetrahydropyranyl.
- Ri is methylene-4,4-difluoro- l -cyclohexyl.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- R 3 -R5, X, and R are as defined in the preceding embodiment.
- R 2 is hydrogen or halo
- R 3 -R5, X, and R are as defined in the preceding embodiment.
- R3-R5, X, and R are as defined in the preceding embodiment.
- R 2 is hydrogen or halo
- R3-R5, X, and R are as defined in the preceding embodiment.
- R 2 -R5 are each independently selected from hydrogen or halo, preferably hydrogen.
- R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring.
- R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6b together form a C3-C5 cycloalkyl ring, preferably methyl. In another embodiment, R 6a and R 6 b together form a C 3 -C 6 cycloalkyl ring, preferably cyclopropyl.
- R 6a and R 6b together form a 3 to 6 membered heterocyclyl ring.
- the heterocyclyl ring is a 5 or 6 membered ring.
- the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
- the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
- R 6a and R 6b are each methyl or R 6a and R 6b together form a cyclopropyl or cyclopentyl ring.
- R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -Cg haloalkenyl, C 2 -C 8 haloalkynyl, C 6 -Ci 2 aryl, C 6 -Ci 2 haloaryl, C 3 -Ci 2 cycloalkyl, Ci-Ci 2 heteroalkyl, C 3 -Ci 2 heterocyclyl, C 6 -Ci 2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl,
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C8 heterocycle.
- each X is independently halo
- each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C 3 -C 8 heterocycle.
- R 6c is cyano.
- each X is independently halo
- each R is independently H, Ci-Cg alkyl, C 6 -Ci 2 aryl, C 6 -Ci2 aryl Ci-Cg alkyl, or C 3 -C 8 heterocycle.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C3-C8 heterocycle.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- R 6c is selected from Ci-C 8 alkylene heterocyclyl, C 2 -C 8 alkynyl, C 6 -Ci 2 aryl, or C 6 -Ci 2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
- R 6c is selected from Ci-C 8 alkylene heterocyclyl, C 2 -C 8 alkynyl, C6-Ci 2 aryl, C 6 -Ci 2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
- the Ci-Cs alkylene heterocyclyl is Ci-C 6 alkylene heterocyclyl. In one embodiment, the Ci-C 6 alkylene heterocyclyl is methylene heterocyclyl. In one embodiment, the heterocyclyl ring is a pyrrolidinyl ring. In one embodiment, the methylene heterocyclyl is methylene pyrrolidinyl, for example methylene-N-pyrrolidinyl.
- the C 2 -C 8 alkynyl is C 2 -C6 alkynyl. In one embodiment, the C 2 -C 6 alkynyl is ethynyl. In one embodiment, the C 6 -Ci2 aryl is phenyl.
- the C 6 -Ci2 haloaryl is halophenyl.
- the halophenyl is chlorophenyl or fluorophenyl.
- R 6c is selected from methylene heterocyclyl, C 2 -C6 alkynyl, phenyl, halophenyl or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
- R 6c is selected from methylene pyrrolidinyl, ethynyl, phenyl, chlorophenyl, fluorophenyl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
- R 6c is selected from Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 6 -Ci2 aryl, C 6 -Ci2 haloaryl, C3-C12 cycloalkyl, or C3-C12 heterocyclyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more halo.
- R 6c is selected from C1-C6 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 haloaryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo.
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl.
- each X is independently halo
- each R is independently H, Ci-Cs alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle;
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
- each X is independently halo
- each X is independently halo
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C 3 -Ci2 heterocycle.
- each X is independently halo
- each R is independently H, Ci-Cg alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-Cg alkyl, or C 3 -Cg heterocycle;
- each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl.
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C6-C i 2 aryl, C p
- R 2 -R5, R 6a , Rfti, R 6 c, Ri 2 a and Ri 2 b are as defined above in the second aspect of the invention, or
- Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl
- Y, B , R 2 -R5, R 6a , 6 b, R 6 c, Ri 2 a and Ri3 ⁇ 4 are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, C i-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C i-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -C i 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R 2 -R5 are each independently selected from hydrogen or halo
- R 6 a> R6b> and R 6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Y, B , R 2 -R5, R 6a , Rib, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R 2 -R5 are hydrogen
- R 6 a, 6 b, and R 6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl;
- Y, B, R 2 -R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R 2 -R5 are hydrogen
- R 6a and R 6 are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
- R 6c is as defined above in the second aspect of the invention, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl; and Y, B, R2-R5, 6a > R6b, and R 6 c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
- R 6c is selected from C1-C6 alkyl, C6-C12 aryl, C 6 -Ci 2 haloaryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, heterocyclyl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R 2 -R5 are hydrogen;
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- R 6c is selected from Ci-C 6 alkyl, C 6 -Cio aryl, C6-C10 haloaryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
- Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl
- Y, B, R2-R5, 6 a, 6 b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Ci-Ce alkylene-4,4-difluoro- 1 -cyclohexyl
- Y, B, R 2 -R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Q-Ce alkylene-4,4-difluoro- 1 -cyclohexyl
- Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Ci-C 6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
- Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
- Ri is selected from Ci-C 6 alkyl, Ci-Ce bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro- l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Ci-C 6 alkylene-4,4-difluoro- 1 -cyclohexyl
- Y, B, R2-R5, R 6 a, R6b, and R 6c are as defined in the preceding embodiment.
- B is selected from CH or N;
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro- l -cyclohexyl
- Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, R 6a , 6 b, and R 6c are as defined in the preceding embodiment.
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring; and R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, 6 a > R6b, and R 6 c are as defined in the preceding embodiment.
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Y, B, R2-R5, R 6 a, R6b, and R 6c are as defined in the preceding embodiment.
- the present invention provides a compound of formula la,
- Yi is selected from O, S, or SO2;
- Y2 is selected from CH2, O, or NH;
- Ri is selected from CH or N;
- Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Q-Q alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
- R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
- R 6a and R 6b are each independently selected from Ci-C 8 alkyl or R6 a and R 6b together form a C3-C6 cycloalkyl ring;
- Ri 2a and R 12b are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
- the present invention provides a compound of formula la,
- Yi is selected from O, S, or S0 2 ;
- Y 2 is selected from CH 2 , O, or NH;
- B is selected from CH or N;
- R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , S0 3 H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, C6-C 2 o aryl, C 3 -C 2 o cycloalkyl, Ci-C 2 o heteroalkyl, C 3 -C 2 o
- R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C 3 -Cg cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
- each X is independently halo
- each R is independently H, C1-C10 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- Cs alkyl, C 3 -Ci 2 cycloalkyl, bridged Cg-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
- the invention provides the present invention provides a compound of formula la,
- R 6a and R 6b together form 3 to 7 membered heterocycle
- Yi, Y 2 , B, Ri, R2-R5 and R7-R11 are as defined in the preceding aspect;
- the present invention provides a compound of formula la,
- Yi is selected from O, S, or S0 2 ;
- Y 2 is selected from CH 2 , O, or NH;
- B is selected from CH or N;
- R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NR 12a R 12b , S0 2 NR 12a R 12b , CONR 12a R 12b , halo, C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, C6-C 2 o aryl, C3-C
- R 6a and R 6b are each independently selected from Ci-C 8 alkyl or R6a and R 6b together form a C 3 -C 6 cycloalkyl ring;
- each X is independently halo
- each R is independently H, C1-C10 alkyl, C 6 -Ci 2 aryl, C6-Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- C 8 alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
- each X is independently halo
- each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
- Ri 2a and Ri 3 ⁇ 4 are each independently selected from hydrogen, Ci-Cg alkyl, or C6-C12 aryl.
- Ri 2a and Ri 3 ⁇ 4 are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
- Yi is selected from O, S, or S0 2> preferably Yi is selected from O or S. In one embodiment, Yi is O.
- Y 2 is selected from CH 2 , O, or NH, preferably Y 2 is selected from NH or O.
- Yi is O; and Y 2 is NH or O.
- Yi is O; and Y 2 is NH.
- B is CH. In one embodiment, B is N.
- each X is independently halo
- each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- C 8 alkyl, C 3 -C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C 3 -C12 cycloalkyl, or a C 3 -C12 heterocycle.
- each X is independently halo
- each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C6-C12 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
- each R is independently H, Ci-Cio alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -C12 cycloalkyl.
- Ri is selected from C1-C6 alkyl, Ci-C 6 bromoalkyl, C1-C6 fluoroalkyl, C 6 -Ci2 aryl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2-bicyclo[2.2.1]heptanyl, C3-C12 cycloalkyl, or Ci-C 6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo.
- Ri is C1-C6 alkylene-4,4-difluoro- l-cyclohexyl.
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene- 3, 3- difluoro-1 -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N- methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2. l]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl.
- Ri is methylene-4,4-difluoro- l -cyclohexyl.
- each X is independently halo
- each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C 3 -C 8 heterocycle.
- R 3 -R5, R7-R11 , X, and R are as defined in the preceding embodiment.
- R 2 is hydrogen or halo
- R 3 -R5, R7-R11 , X, and R are as defined in the preceding embodiment.
- R3-R5, R7-R 11 , X, and R are as defined in the preceding embodiment.
- R 2 is hydrogen or halo
- R3-R5, R7-R 11 , X, and R are as defined in the preceding embodiment.
- R 2 -R5, R7- R 11 are each independently selected from hydrogen or halo.
- R 2 -R5, R7, Rs, Rio, and Rn are hydrogen and R is halo. In one embodiment, R 2 -R5, R7, Rs, Rio, and Rn are hydrogen and R9 is fluoro.
- R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring. In one embodiment, R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6b together form a C3-C5 cycloalkyl ring.
- R 6a and R 6b are each methyl or R 6a and R 6b together form a cyclopropyl or cyclopentyl ring.
- R 6a and R 6b together form a 3 to 6 membered heterocyclyl ring.
- the heterocyclyl ring is a 5 or 6 membered ring. In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
- the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
- R 6a and R 6b are each independently methyl.
- R 6a and R 6b together form a cyclopropyl ring.
- Yi is selected from O, S, or S0 2 ;
- Y 2 is selected from CH 2 , O, or NH;
- each R is independently H, Ci-Cio alkyl, C6-C12 aryl, C 6 -Ci 2 fluoroaryl, C6-C12 aryl Ci- Cs alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle.
- Yi is O
- Y 2 is selected from NH or O
- each R is independently H, Ci-Cio alkyl, C 6 -Ci2 aryl, C6-C 12 fluoroaryl, C 6 -Ci2 aryl Cp Cg alkyl, C3-C 12 cycloalkyl, bridged C 6 -C i2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
- Yi is O
- Y2 is selected from NH
- each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
- each R is independently H, C 1-C 10 alkyl, C 6 -Ci2 aryl, C 6 -C i2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -C 12 cycloalkyl.
- Yi is selected from O or S;
- Y 2 is selected from CH 2 , O, or NH;
- Ri, R2-R5, R6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri, R2-R5, 6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
- R2-R5, R 6a , R6b, R7-R11, Ri2a and Ri 2 b are as defined above in the sixth aspect of the invention, or
- Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, R7-R11, Ri2a and Ri 2 b are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen or halo
- R 6a , R 6b , and R7-R11 and Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, 6 a, R 6 b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O; B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6 a, 6b , and R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, 6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene-
- Ci-C 6 alkylene-p-fluoro-phenyl Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO 3 H, halo, Ci-Cs alkyl, or Ci-C 8 alkoxy, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, 6 a, R 6b , and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene-
- Ci-C 6 alkylene-p-fluoro-phenyl Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C 6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R7-R11 are each independently selected from hydrogen, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or a pharmaceutically acceptable salt or prodrug thereof.
- Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6b , and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- R7-R11 are each independently selected from hydrogen or halo, or
- Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6a , R 6b , and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C 6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen; R 6a and R 6 are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring; and
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and Rg b together form a cyclopropyl ring;
- Rg is fluoro
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is C1-C6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y2, B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-C 6 alkyl, C1-C6 bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
- R9 IS fluoro
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is Q-Ce alkylene-4,4-difluoro- l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- Rg is fluoro
- R7, Rg, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro- l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6b , and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S; Y 2 is selected from NH or O;
- B is selected from CH or N;
- Ri is selected from Ci-C 6 alkyl, Ci-C 6 bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C alkylene-cycloheptanyl, Ci-C alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is C1-C0 alkylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is selected from CH or N;
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro- l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S; Y 2 is selected from NH or O;
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
- Rg is fluoro
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 together form a cyclopropyl ring;
- Rg is fluoro
- R7, Rg, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S; Y 2 is selected from NH or O;
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b > and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- Rg is fluoro
- R 7 , Rs, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring
- R9 IS fluoro
- R7, Rs, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring
- R9 IS fluoro
- R7, Rg, Rio, and Rn are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro- l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a > R 6b , and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro- l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6a , R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b are each independently selected from methyl
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y2 is selected from NH or O
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring; and R 7 - Rii are hydrogen, or
- Ri is methylene-4,4-difluoro-l-cyclohexyl
- Yi, Y 2 , B, R2-R5, 6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- Yi is selected from O or S;
- Y 2 is selected from NH or O
- B is CH
- Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
- R2-R5 are hydrogen
- R 6a and R 6 b together form a cyclopropyl ring
- R7- R11 are hydrogen, or
- Ri is methylene-4,4-difluoro-l -cyclohexyl
- Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
- the compound of the invention is SGT-23, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-24, or a pharmaceutically acceptable salt or prodrug thereof
- the compound of the invention is SGT-25, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-41, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-42, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-55, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-56, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-60, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-65, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is SGT-67, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is acceptable salt or prodrug thereof.
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the com ound of the invention is
- the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of the invention is selected from the group comprising: SGT-23, SGT-24, SGT-25, SGT-41, SGT-42, SGT-55, SGT-56, SGT-60, SGT-65, SGT-67, MJ1-MJ12, MJ14, and MJ15, or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of the invention is selected from the compounds listed in Tables 1, 2, and 3 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1 and 2 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof.
- Asymmetric centres may exist in the compounds of the invention.
- the asymmetric centres may be designated by the symbols "R” or “S”, depending on the configuration of substituents in three dimensional space at the chiral carbon atom. All stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1- isomers, and mixtures thereof of the compounds are contemplated herein.
- Individual enantiomers of the compounds can be prepared synthetically from commercially available enantiopure starting materials or by preparing enantiomeric mixtures of the compounds and resolving the mixture into individual enantiomers.
- Resolution methods include conversion of the enantiomeric mixture into a mixture of diastereomers and separation of the diastereomers by, for example, recrystallisation or chromatography; direct separation of the enantiomers on chiral chromatographic columns; and any other appropriate method known in the art.
- d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
- a compound prefixed with (+) or d is dextrorotatory.
- these stereoisomers are identical except that they are mirror images of one another.
- a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
- a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereo specificity in a chemical reaction or process.
- racemic mixture and racemate refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
- the compounds of the invention may also exist as geometric isomers. All cis, trans, syn, anti,
- Z) isomers, as well as the appropriate mixtures thereof of the compounds are contemplated herein.
- the compounds may also exist as tautomers, for example, keto/enol; imine/enamine;
- the compounds may also exist as isotopologues and isotopomers, wherein one or more atoms in the compounds are replaced with different isotopes.
- Suitable isotopes include, for example, 2 H (D), 3 H (T), 12 C, 13 C, 14 C, 16 0, and ls O.
- the compounds may exist in solvated or unsolvated forms. If the solvent is water, the solvate may be referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, or a tri-hydrate. All solvates of the compounds are contemplated herein.
- Salts of the compounds of the invention include, for example, acid addition salts, base addition salts, and quaternary salts of basic nitrogen-containing groups.
- Acid addition salts can be prepared by reacting compounds, in free base form, with inorganic or organic acids.
- inorganic acids include, but are not limited to, hydrochloric; hydrobromic; hydroiodic; nitric; carbonic; sulfuric; and phosphoric acid.
- organic acids include, but are not limited to, cholic; sorbic; lauric; acetic; trifluoroacetic; formic; propionic; succinic; glycolic; gluconic; digluconic; lactic; malic; tartaric; citric; ascorbic; glucuronic; maleic; fumaric; pyruvic; aspartic; glutamic; aryl carboxylic; anthranilic acid; mesylic; stearic; salicylic; phenylacetic; mandelic; embonic (pamoic); alkylsulfonic; ethanesulfonic; arylsulfonic; benzenesulfonic; pantothenic; sulfanilic;
- cyclohexylaminosulfonic ⁇ -hydroxybutyric; galactaric; galacturonic; adipic, alginic; butyric; camphoric; camphor sulfonic; cyclopentanepropionic; dodecylsulfic; glycoheptanoic;
- glycerophosphic heptanoic; hexanoic; nicotinic; 2-naphthalesulfonic; oxalic; palmoic;
- pectinic 3-phenylpropionic; picric; pivalic; thiocyanic; tosylic; and undecanoic acid.
- Base addition salt can be prepared by reacting compounds, in free acid form, with inorganic or organic bases.
- base addition salts include metal salts and organic salts.
- Preferred metal salts include alkali metal salts, alkaline earth metal salts, and other physiologically acceptable metal salts.
- the metal salt comprises aluminium, calcium, lithium, magnesium, potassium, sodium, or zinc.
- Organic salts may be made from amines, such as trimethylamine, diethylamine, N,N-dibenzylethylenediamine,
- chloroprocaine ethanolamine, diethanolamine, ethylenediamine, meglumine ( ⁇ - methylglucamine), and procaine.
- LG is an appropriate leaving group and includes halo, tosyl, triflate, mesyl, and any other highly stabilised anionic leaving group.
- Such leaving groups are known to those of skill in the art.
- ⁇ means azobisisobutyronitrile.
- NBS N-bromo succinimide.
- DCM dichloromethane (CH 2 CI 2 ).
- Et means ethyl.
- EtOAc means ethylacetate.
- Me means methyl (-CH 3 ).
- MeOH means methanol.
- MeCN means acetonitrile.
- Pr means propyl.
- i-Pr means isopropyl (-CH(CH 3 )2).
- i-PrOH means isopropanol.
- rt means room temperature.
- THF means tetrahydrofuran.
- TLC means thin layer chromatography.
- protecting groups include prodrug moieties and chemical protecting groups.
- PG Protecting groups
- PG are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical PG will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis.
- the PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG.
- PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency.
- PGs for -OH groups include "ether- or ester-forming groups”.
- Ether- or ester-forming groups are capable of functioning as chemical PGs in the synthetic schemes set forth herein.
- some hydroxyl and thio PGs are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
- phosphonamidate esters phosphorothioate esters, phosphonate esters, and phosphon-bis- amidates
- carboxyl ester- forming groups and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate.
- the compounds of the invention may be synthesised according to the general methods described below.
- Compounds of formula (Ha), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed.
- many compounds of formula (lib) wherein LG is halo, for example bromo are commercially available.
- compounds of (lib) may be prepared from their corresponding alcohols.
- compounds of formula (lib) wherein LG is, for example, tosyl or mesyl may be prepared from the corresponding alcohol by reaction with p-toluene sulfonyl chloride or methane sulfonyl chloride and a base such as triethylamine in dichloromethane.
- a compound of formula (Ila) together with an appropriate base, such as sodium hydride is stirred in an anhydrous solvent at 0°C.
- a solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ila), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
- Suitable reaction conditions would be known to one of skill in the art or could be found in /. Med. Chem. 1991 ; 34(3): 1099- 1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
- the compound of formula (lie) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, crystallisation, or preparative HPLC.
- a solution containing a halogenating agent, such as thionyl chloride, oxalyl chloride, or phosphorous oxychloride, in an anhydrous solvent is added dropwise to a stirred solution of compound (lie) in the same anhydrous solvent at 0°.
- a stirred solution of compound (lie) in the same anhydrous solvent at 0°.
- the resulting mixture is stirred at 0°C for at least 30 minutes, returned to room temperature, and stirred for at least 30 minutes.
- the mixture is then cooled to 0°C.
- a solution containing compound (lid) and a base such as triethylamine or
- the first step of the synthesis is as described above with respect to General method A.
- an activating agent such as N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU) or ⁇ , ⁇ -dicyclohexylcarbodiimide (DCC)
- HBTU N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate
- DCC ⁇ , ⁇ -dicyclohexylcarbodiimide
- the reaction mixture is allowed to warm to room temperature and then stirred for 12 hours.
- a base such as diisopropylethylamine is added to reaction mixture following the addition of the activating agent.
- the order of addition of the reagents may be varied, as appropriate.
- Standard work-up and, optionally, purification provide the compound of formula (He).
- the reaction mixture is filtered through Celite, concentrated under reduced pressure , and then purified by column chromatorgraphy and then crystallisation from an appropriate solvent or mixture of solvents, for example a mixture of hexane-ethyl acetate.
- General method C Compounds of formula (He) can also be prepared using the synthetic route detailed in Scheme IB, in which R l5 R2-R5, R6 a -R6c > Yi, Y 2 , and B are as defined for the compounds of the invention and LG is an appropriate leaving group.
- a compound of formula (Ila) is coupled with a compound of formula (lid).
- the compound of formula (Ila) is treated with a suitable activating agent, for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU), in an ahydrous aprotic organic solvent, typically N,N-dimethylformamide (DMF), at ambient temperature under an atmosphere of argon.
- a suitable activating agent for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU)
- HBTU ahydrous aprotic organic solvent
- DMF N,N-dimethylformamide
- activating agents may be used, depending on the nature and reactivity of the compound of formula (lib).
- compounds of formula (lib) wherein one or more of R2-R5 is halo for example fluoro
- N,N- dicyclohexylcarbodiimide (DCC) may be used as the activating agent.
- DCC N,N- dicyclohexylcarbodiimide
- a wide range of activating agents are known in the art for activating, for example, carboxylic acid groups for reaction with alcohols and amines.
- a base such as triethylamine or diisopropylamine
- a base is then added dropwise at ambient temperature over suitable period of time, for example 2 hours.
- the period of time over which the base is added may depend on the scale of the reaction.
- reaction mixture is then stirred at ambient temperature for 15 hours before gradually heating to 120°C, for example at 25°C per hour, and then heating at 120°C for 3 hours.
- the progress of the reaction may be monitored by any suitable means known in the art, for example thin layer chromatography or HPLC.
- Standard workup and, optionally, purification provides the compound of formula (X).
- the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then saturated sodium carbonate solution added and resultant mixture cooled to below 5°C to form a precipitate.
- the precipitate is filtered and washed with water, triturated with saturated sodium carbonate solution, and then filtered and washed again with water. Finally, toluene is added and then evaporated to provide the compound of formula (X).
- reaction is carried out by combining the compound of formula (X) and anhydrous potassium carbonate in a suitable solvent, for example anhydrous DMF, and then adding the compound of formula (lib) at ambient temperature. The reaction mixture is then heated at 70°C for 15 hours.
- a suitable solvent for example anhydrous DMF
- Standard workup and, optionally, purification provides the compound of formula (He).
- the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then ethyl acetate added.
- the mixture is then poured onto ice and, once the ice has melted, the organic layer separated.
- the aqueous layer is then extracted with ethyl acetate, and the combined organic extracts washed with sodium carbonate solution, then dried over sodium sulfate and filtered.
- the solvent is removed, ethyl acetate added and the solution passed through silica. Fractions containing the compound of formula (He) are combined and the solvent removed to provide the desired compound.
- Other workup and purification methods may be used, as appropriate.
- a compound of formula (IIIc) can be prepared using the synthetic route detailed in Scheme 2, in which, Ri, R2-R5, R6 a -R6c > Y 2 , and B are as defined for the invention, and LG is an appropriate leaving group.
- Compounds of formula (Ilia), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed.
- a compound of formula (Ilia) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C.
- a solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ilia), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
- the compound of formula (Illb) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (Illb). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
- a solution containing compound (Illb), AIBN, and NBS in a halogenated solvent and acid is stirred at room temperature for at least five minutes, and then irradiated for at least 4 hours.
- Water may be added and the mixture extracted with a halogenated solvent.
- the compound of formula (IIIc) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, a halogenated solvent and water is added to the reaction mixture containing the compound of formula (IIIc).
- the aqueous phase is extracted with a halogenated solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate.
- the combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
- the compounds of the invention may also be synthesised according to the schemes described below using the techniques set out in general methods A and B and using reaction conditions known to those of skill in the art.
- Ri, R2-R5, R6a-R6c, PG, and B are as defined for the invention, and LG is an appropriate leaving group.
- compositions of the invention comprise one or more compounds of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients.
- the carriers must be "acceptable” in the sense of being compatible with the other ingredients of the composition and physiologically innocuous to the recipient.
- the carrier must also be suitable for the mode of administration of the active agent.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a
- compositions containing the active ingredient may be in any form suitable for the intended method of administration.
- Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.
- gel, caps, tablets, troches, lozenges, aqueous or oil When used for oral use for example, gel, caps, tablets, troches, lozenges, aqueous or oil
- compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions.
- Such compositions may contain one or more agents including sweetening agents, flavouring agents, colouring agents and preserving agents, in order to provide a palatable preparation.
- the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain carriers, excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All compositions will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety.
- Carriers and excipients include methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
- the pH of the compositions ranges from about 3 to about 11, but is ordinarily about 7 to 10.
- the compound of the invention may exist in a suspension.
- Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorb
- the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, such as sucrose or saccharin.
- preservatives such as ethyl or n-propyl p-hydroxy-benzoate
- colouring agents such as ethyl or n-propyl p-hydroxy-benzoate
- flavouring agents such as sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
- a dispersing or wetting agent e.g., a suspending agent
- Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth herein, and flavouring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
- Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
- the emulsion may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
- sweetening agents such as glycerol, sorbitol or sucrose.
- Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
- the oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
- the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of cream compositions.
- Emulgents and emulsion stabilisers suitable for use in the composition of the invention include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
- Oral compositions include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
- the composition of the invention is an oral composition.
- the composition is in the form of a pill, tablet, or dragee.
- a tablet is made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable carrier, which is suitable for manufacture of tablets.
- non-toxic pharmaceutically acceptable carrier may be, for example, inert diluents, such as 2-hydroxypropyl beta-cyclodextrin, methylsulfonylmethane (MSM), mannitol, calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatine or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including
- the composition of the invention comprises methylsulfonylmethane (MSM) as the carrier.
- MSM methylsulfonylmethane
- the composition of the invention comprises 2- hydroxypropyl beta-cyclodextrin as the carrier.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules (gel caps), cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be administered as a bolus, electuary or paste.
- compositions for oral use may be also presented as hard gelatine capsules (gel caps) where the active ingredient is mixed with an inert solid carrier, for example methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- MSM methylsulfonylmethane
- 2-hydroxypropyl beta-cyclodextrin mannitol
- mannitol calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- an oral pharmaceutical composition of the invention is prepared as follows: a compound of the invention is dissolved in a solvent, such as acetone or diethyl ether, and is mixed with a suitable diluent at a ratio of active ingredient:diluent of 1:99.
- suitable diluents include those that are approved for use in food, dietary supplements, or tabletting, and may include 2-hydroxypropyl beta-cyclodextrin, mannitol or
- methylsulfonylmethane more preferably methylsulfonylmethane.
- Optional carriers and/or excipients may also be added. The solvent may then be removed.
- the resulting powder may be then divided up into capsules or pressed into tablets.
- compositions suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 ⁇ (including particle sizes in a range between 0.1 and 500 ⁇ in increments such as 0.5 ⁇ , 1 ⁇ , 30 ⁇ , 35 ⁇ , etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
- Suitable compositions include aqueous or oily solutions of the active ingredient.
- Compositions suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other suitable therapeutic agents.
- an inhalable composition of the invention comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
- an inhalable composition of the invention is prepared as follows: a compound of the invention is dissolved in a solution of water and propylene glycol, and optionally a surfactant, a fungicide, and/or a bacteriostatic agent.
- the ratio of propylene glycohwater may be in the range of 0.5: 10 to 3: 10, preferably 1.5: 10.
- the ratio of surfactant:water may be in the range of 0.001: 10 to 0.5:10, preferably 0.05:10.
- the surfactant, if present may be Tween 20.
- a compound of the invention is dissolved initially in propylene glycol with stirring.
- a surfactant, a fungicide, and/or a bacteriostatic agent is then added followed by water.
- the mixture is heated with stirring to ensure the compound of the invention dissolves into solution.
- the mixture is administered nasally.
- An e-cigarette is an electronic inhaler that vaporises a liquid solution (e-liquid) into an aerosol mist, simulating the act of tobacco smoking.
- the invention provides an e-liquid comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
- the e-liquid is a mixture of propylene glycol and glycerine, preferably vegetable glycerine.
- the e-liquid has a preferred ratio of propylene glycokglycerine may be from 1:1 to 4: 1, more preferably 3:2.
- the e-liquid further comprises a flavour enhancer, such as Tasty Puff or similar.
- the e-liquid optionally includes a surfactant to enhance solubility.
- the surfactant may be present at a concentration of between 0.01% and 5% by weight, more preferably 0.5% by weight.
- the surfactant may be chosen from the group consisting of Triton X- 100, Tween 20 and Tween 60, more preferably Tween 20.
- an e-liquid of the invention may be prepared as follows: the compound of the invention is dissolved in propylene glycol, which may be at room temperature or heated. Preferably, the propylene glycol is heated to 60-90 °C, preferably 80 0 C, with stirring until the compound of the invention is in solution.
- Vegetable glycerine and optionally a surfactant, is added with stirring, and the mixture is allowed to slowly return to room temperature. The mixture may be filtered. A smoking composition is intended to be smoked in a cigarette or pipe.
- the invention provides a smoking composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
- a smoking composition of the invention is prepared as follows: the compound of the invention is dissolved in acetone and then mixed with a base herb in a large mixing machine.
- the base herb is selected from damiana, marshmallow, mugwort, passionflower, lion's tail, blue lotus, calea zacatechichi and salvia divinorum, more preferably damiana.
- food colours are added to the acetone solution to colour the final product.
- the mixture is mixed for approximately 30-60 minutes, preferably approximately 40 minutes to ensure even distribution of the compound of the invention through the base herb.
- the wet mixture is dried to remove the acetone.
- the dry mixture is then ready for packing and use.
- the dry mixture is sprayed with flavouring agents, which are dissolved in a propylene glycol and/or ethanol base.
- flavouring agents which are dissolved in a propylene glycol and/or ethanol base.
- the mixture is mixed in a mixing machine after being sprayed with a flavouring agent, and then dried for approximately 30 minutes before packing and use.
- a preferred blend contains 500g of the compound of the invention and 1kg of powdered food colour (e.g. Brilliant Blue) dissolved in 6 litres of acetone sprayed onto 25kg of damiana. The mixture is then dried over a 12 hour period before being sprayed with 2.5 litres of "Tasty Puff flavour liquid.
- powdered food colour e.g. Brilliant Blue
- compositions of the invention may be administered topically, for example in a cream.
- the composition of the invention is a topical composition.
- the composition is in the form of an ointment, cream, eye drop, or paste.
- the choice of suitable oils or fats for a topical composition is based on achieving the desired cosmetic properties.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters.
- the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
- the topical compositions may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogues.
- compositions suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
- the active ingredient is preferably present in such compositions in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
- the compositions are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
- the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
- the active ingredients may be formulated in a cream with an oil-in-water cream base.
- compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerine, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- the composition of the invention is an oral topical composition, preferably the composition is in the form of a lozenge.
- compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
- a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilised powder.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils may conventionally be employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid may likewise be used in the preparation of injectables.
- the composition of the invention is an injectable composition.
- compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- compositions for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Controlled release compositions of the invention may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provides compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
- the composition of the invention is a time-release composition.
- a time-release composition intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight).
- the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
- an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per millilitre (ml) of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
- compositions of the invention include those suitable for the foregoing administration routes.
- the compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
- the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- compositions are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
- sterile liquid carrier for example water for injection
- Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
- Preferred unit dosage compositions are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
- compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example those suitable for oral
- administration may include flavouring agents.
- the effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies.
- the effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg kg body weight per day.
- the daily candidate dose for an adult human of approximately 70 kg body weight will range from 0.01 mg to 1000 mg, or between 0.05 mg and 500 mg, and may take the form of single or multiple doses.
- the composition of the invention is in a dosage form which contains at least 0.001 mg of the compound of the invention, preferably 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, or 500 mg of the compound of the invention.
- the composition of the invention is in a dosage form which contains 0.001-500 mg of the compound of the invention, preferably 0.005-500, 0.01-500, 0.05-500, 0.1-500, 0.2-500, 0.3-500, 0.4-500, 0.5-500, 0.6-500, 0.7-500, 0.8-500, 0.9-500, 1-500, 2- 500, 3-500, 4-500, 5-500, 6-500, 7-500, 8-500, 9-500, 10-500, 15-500, 20-500, 25-500, 30- 500, 35-500, 40-500, 45-500, 50-500, 60-500, 75-500, 80-500, 85-500, 90-500, 95-500, 100- 500, 110-500, 120-500, 130-500, 140-500, 150-500, 150-500, 160-500, 170-500, 180-500, 190-500, 200-500, 250-500, 300-500, 350-500, 400-500, or 450-500 mg of the compound of the compound
- the dosage form is in an inhalable, topical, oral, smokable, or injectable dosage form.
- the composition of the invention is an e-liquid which contains at least 0.1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/ml of the compound of the invention.
- the composition of the invention is an e-liquid which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5- 200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120- 200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/ml of the compound of the invention.
- the composition of the invention is a smoking composition which contains at least 0.1 mg/g of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
- the composition of the invention is smoking composition which contains 0.1-200 mg/g of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4- 200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40- 200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/g of the compound of the invention.
- the composition of the invention is an inhalable composition which contains at least 1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
- the composition of the invention is an inhalable composition which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190- 200 mg/ml of the compound of the invention.
- the compounds of the invention bind to CBi and/or CB 2 receptors.
- Compounds that bind to these receptors are known to have gastrointestinal, cardiovascular, and/or central nervous system activity.
- the compound of the invention is a CBi and/or CB 2 receptor agonist.
- the EC50 of the compound of the invention in a CBi and/or CB 2 receptor affinity assay is less than about 1000 ⁇ , 500 ⁇ , 250 ⁇ , 100 ⁇ , 50 ⁇ , 25 ⁇ , 10 ⁇ , 5 ⁇ , 3 ⁇ , 1 ⁇ , 750 ⁇ , 500 ⁇ , 400 ⁇ , 300 ⁇ , 200 ⁇ , 100 ⁇ , 90 ⁇ , 80 ⁇ , 70 ⁇ , 60 ⁇ , 50 ⁇ , 40 ⁇ , 20 ⁇ , 10 ⁇ , 9 ⁇ , 8 ⁇ , 7 ⁇ , 6 ⁇ , 5 ⁇ , 4 ⁇ , 3 ⁇ , 2 nM, 1 ⁇ , 0.9 ⁇ , 0.8 ⁇ , 0.7 ⁇ , 0.6 ⁇ , 0.5 ⁇ , 0.4 ⁇ , 0.3 ⁇ , 0.2 ⁇ , 0.1 ⁇ , 0.05 ⁇ , 0.01 ⁇ , 0.001 nM, or 0.0001 nM, and useful ranges may be selected between any of these values.
- the EC50 is from about 0.0001 nM to about 1000 ⁇ , from about 0.0001 nM to about 100 ⁇ , from about 0.0001 to about 10 ⁇ , from about 0.001 nM to about 500 ⁇ , from about 0.001 nM to about 100 ⁇ , from about 0.001 nM to about 50 ⁇ , from about 0.001 nM to about 10 ⁇ , from about 0.001 nM to about 5 ⁇ , from about 0.01 nM to about 500 ⁇ , from about 0.01 nM to about 100 ⁇ , from about 0.01 nM to about 50 ⁇ , from about 0.01 nM to about 10 ⁇ , from about 0.01 nM to about 5 ⁇ , from about 0.05 nM to about 500 ⁇ , from about 0.05 nM to about 100 ⁇ , from about 0.05 nM to about 50 ⁇ , from about 0.05 nM to about 10 ⁇ , or from about 0.05 nM to about 5 ⁇ .
- the CBi and/or CB 2 receptor affinity assay measures the effect of the compound on cAMP modulation using the HTRF detection method.
- the CBi and/or CB 2 receptor affinity assay is substantially as described herein in the Examples. The inventors have advantageously found that certain compounds of formula (I) exhibit selective affinity for CBi and/or CB 2 .
- the compound of the invention is a selective CBi and/or CB 2 receptor agonist.
- the compound of the invention is selective for CBi and/or CB 2 over at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic ⁇ , adrenergic ⁇ 2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, ta
- the compounds is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, or 10000 times more selective for CBi and/or CB 2 than for the G-protein coupled receptor or ligand-gated ion channel.
- Selectivity may be measured by any suitable method known in the art, for example by comparing the Ki or EC50 of the compound for CBi and/or CB 2 with the Ki or EC50 of the compound for the G-protein coupled receptor or ligand-gated ion channel.
- the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic al, adrenergic ⁇ , adrenergic ⁇ 2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dop
- the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
- control specific binding and/or control specific binding is measured using a reference radioligand for each G-protein coupled receptor and ligand- gated ion channel.
- the reference radioligand is as defined in Table 6 below.
- the invention relates to a use of a compound of the invention in the
- the invention related to use of a compound of the invention in the manufacture for treating nausea and/or emesis in a subject.
- the invention relates to a use of a compound of the invention in the manufacture of a medicament for stimulating appetite in a subject.
- the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a euphoric effect in a subject.
- the invention relates to a use of a compound of the invention in the manufacture of a medicament for relaxing a subject in a subject.
- the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a positive mood change in a subject.
- the invention in another aspect, relates to a method of treating pain in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention relates to a method for treating nausea and/or emesis in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention relates to a method for stimulating appetite in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention relates to a method of inducing a euphoric effect in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention relates to a method of relaxing a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention relates to method of inducing a positive mood change in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
- the invention in another aspect, relates to a compound of the invention for use in treating pain in a subject.
- the invention relates to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject.
- the invention in another aspect, relates to a compound of the invention for use in inducing a euphoric effect in a subject.
- the invention in another aspect, relates to a compound of the invention for use in relaxing a subject.
- the invention in another aspect, relates to a compound of the invention for use in inducing a positive mood change in a subject.
- the nausea and/or emesis is caused by injury, pain, cancer, AIDS, tuberculosis, glaucoma, menstruation, hepatitis, chemotherapy, radiotherapy, or headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches).
- the appetite is stimulated to treat loss of appetite caused by wasting.
- the wasting is caused by cystic fibrosis, anorexia, old age, cancer, AIDS, tuberculosis, chronic diarrhoea, or cachexia, preferably cancer cachexia.
- the pain is selected from nociceptive pain, neuropathic pain, or psychogenic pain.
- the nociceptive pain is caused by: inflammation, joint pain (such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury), headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches), back pain (such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural deformities (such as scoliosis, kephosis, or lordosis)), fibromyalgia, surgery, or trauma.
- joint pain such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury
- headaches such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches
- back pain such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural
- the neuropathic pain is caused by: multiple sclerosis, phantom limb pain, peripheral (diabetic) neuropathy, post-mastectomy pain, sciatica, spinal cord injury (such as bulging or slipped discs or trauma), carpel tunnel syndrome, cancer, radiotherapy, chemotherapy, radiation injury, surgery, or HIV- associated peripheral neuropathy.
- the psychogenic pain is caused by: headache, muscle pain, back pain, or stomach pain.
- the pain is atypical or neuropathic pain.
- the pain is phantom limb pain.
- One or more compounds of the invention (herein also referred to as the active ingredients) are administered by any route appropriate to the condition to be treated.
- Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example the condition of the recipient.
- An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
- SGT-24 was synthesised according to Scheme 1 (as shown above).
- l-Pentyl-lH-indazole-3-carboxylic acid (lie) was prepared by reaction of commercially available indazole-3-carboxylic acid (Ila) with 1-bromopentane (lib) in the presence of sodium hydride in dimethylformamide. Reaction conditions were as set out in J. Med. Chem. 1991; 34(3): 1099-1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
- Oxalyl dichloride (5.74 g, 45.2 mmol) was slowly added to a stirred solution of 1-pentyl-lH- indazole-3-carboxylic acid (10.0 g, 43.0 mmol) in dichloromethane (100 mL) at 0°C in an ice-bath. The reaction was stirred for 30 minutes. Triethylamine (9.0 mL, 64.58 mmol) was then added, followed by 2-phenylpropan-2-amine (5.82g, 43.0 mmol). The reaction was stirred for 1 hour and monitored by TLC. The reaction was diluted with water and separated into phases.
- N,N-diisopropylethylamine (215 mL, 2.0 molar eq.) drop wise over a period of at least 2 hours.
- the reaction mixture was then stirred for at least 15 hours at ambient temperature under an argon blanket.
- the reaction mixture was the gradually heated in increments of 25 °C per hour up to an internal temperature of 120°C. Once the reaction mixture reached 120°C, it was continuously heated at an internal temperature of 120°C for at least 3 hours.
- the reaction mixture was rotary evaporated to remove the DMF that a bath temperature of 80°C under reduced pressure.
- the crude product was placed in an ice bath and mixed with saturated sodium carbonate solution (10 volumes, 1 L).
- the resultant mixture was continuously stirred and the ice bath until the internal temperature dropped below 5°C.
- a beige coloured precipitate formed that was filtered and washed with cold purified water (10 x 2.5 volumes, 10 x 250 mL).
- the wet filter cake was then triturated in saturated sodium carbonate solution (5 volumes, 500 mL) for at least one hour at room temperature.
- the suspension was then filtered and rinsed with purified water (5 1 volume, 5 x 100 mL).
- the resultant product was dried under air vacuum, and then co-evaporated with toluene four times prior to final drying on a rotary evaporator with a bath temperature of 60°C to constant weight.
- the evaporated residue was mixed with ethyl acetate (5 volumes) and then poured into ice (5 weight equivalents). The mixture was stirred until the ice melted. The bilayer was separated and the aqueous layer extracted with ethyl acetate (4 x 3 volumes). The combined extracts were washed with 50% saturated sodium carbonate solution (4 x 1 volume), then dried over sodium sulfate and filtered. The filtrate was evaporated at a 40° bath temperature and co-evaporated with ethyl acetate (3 x 2.5 volumes). The resultant residue was redissolved and hot ethyl acetate (4 volumes) and filtered through 60 angstrom silica (2.5 volumes) topped with a layer of anhydrous sodium sulphate.
- the filter bed was washed with hot ethyl acetate (2 volumes per fraction) until all of the product was released.
- Product containing fractions were evaporated with a bath temperature of 40°C.
- the crude product was triturated with methyl tert-butyl ether (MTBE)(2 volumes) at room temperature of the 2 hours, and then in an ice bath for one hour.
- the suspension was filtered, then rinsed with cold MTBE (4 x 1 volume).
- the resulting white solid was then dried under vacuum to constant weight, mp 112.7 ⁇ 0.5 .
- SGT 174 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha)
- SGT 211 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha) to provide the desired l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) was carried out according to the general procedure described above for SGT 174.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates generally to cannabinoid compounds, more particularly indole and indazole compounds of formula I and la and pharmaceutical compositions comprising the compounds. The compounds are useful treating pain, treating nausea and/or emesis, stimulating appetite, inducing a euphoric effect, inducing relaxation, and inducing a positive mood change, in particular for treating pain, treating nausea and/or emesis, and stimulating appetite.
Description
CANNABINOID COMPOUNDS
1. FIELD OF THE INVENTION The present invention relates generally to cannabinoid compounds and compositions, more particularly new indole and indazole cannabinoids and compositions, and applications of these.
2. BACKGROUND OF THE INVENTION
Cannabinoids are a class of diverse chemical compounds that activate cannabinoid receptors. The broader definition of the term "cannabinoids" refers to a group of compounds that are structurally related to tetrahydrocannabinol (THC) or that bind to cannabinoid receptors. Such compounds include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (produced chemically by humans). The most notable cannabinoid is delta-9 THC, the primary psychoactive compound of cannabis. However, there are numerous other known synthetic and natural cannabinoids. Delta-9 THC, the principle active component of cannabis, is a member of a large family of cannabinoid compounds that mediate physiological and psychotropic effects including immunosuppression, analgesia, inflammation, emesis, and intraocular pressure.
Cannabinoids work through selective binding to G-protein coupled cannabinoid receptors. Two types of cannabinoid receptors have been cloned: CBi and CB2. The CBi receptor is found mainly on cells of the central nervous system, while the CB2 receptor is found mainly on cells of the peripheral nervous system including cells comprising the immune system, such as lymphoid cells.
Cannabinoid compounds that bind to CBi and/or CB2 receptors, such as delta-9 THC, are known to have gastrointestinal, cardiovascular, and/or central nervous system activity. Such
compounds may, therefore, offer therapeutic approaches to a variety of diseases or conditions.
There is a need to provide alternatives to known cannabinoid compounds. It is an object of the invention to at least go some way towards meeting this need, and/or to at least provide the public with a useful choice.
In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
3. SUMMARY OF THE INVENTION
In a first aspect, the present invention provides a compound of formula I,
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NR12aRi2b, CONRi2aRi2b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cr Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a second aspect, the present invention provides a compound of formula I,
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl,
haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cs alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cs alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C2-Cs haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a third aspect, the invention provides the present invention provides a compound of formula I,
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Y, B, Ri, R2-R5, and R6c are as defined in first aspect above;
a pharmaceutically acceptable salt or prodrug thereof.
In a fourth aspect, the invention provides the present invention provides a compound of formula I,
wherein
R6c is cyano; and
Y, B, Ri, R2-R5, R6a and R6b are as defined in the first aspect above;
a pharmaceutically acceptable salt or prodrug thereof. a fifth aspect, the invention the present invention provides a compound of formula la,
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Q-Q alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each
of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or 3 to 7 membered heterocyclyl ring; and
Ri2a and R12b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-Cg alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a sixth aspect, the presen la la,
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONR12aRi2b, COR12a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-Cg haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In seventh aspect, the invention provides the present invention provides a compound of formula la,
R6a and R6b together form 3 to 7 membered heterocycle; and
Yi, Y2, B, Ri, R2-R5 and R7-R11 are as defined in fifth aspect above;
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
In another aspect, the invention relates to a compound of the invention for use in treating pain in a subject.
In another aspect, the invention related to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
In another aspect, the invention relates to a compound of the invention for use in relaxing a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a positive mood change in a subject.
To those skilled in the art to which the invention relates, many changes in construction and widely differing embodiments and applications of the invention will suggest themselves without departing from the scope of the invention as defined in the appended claims. The disclosures and the descriptions herein are purely illustrative and are not intended to be in any sense limiting Other features of the invention may become apparent from the following description which is given by way of example only.
4. BRIEF DESCRIPTION OF THE DRAWINGS The invention will now be described with reference to the Figures in which:
Figure 1 shows a 1H NMR scan for the compound SGT-42.
Figure 2 shows a 13C NMR scan for the compound SGT-42. 5. DETAILED DESCRIPTION OF THE INVENTION
5.1 Definitions
As used herein "(s)" following a noun means the plural and/or singular forms of the noun. As used herein the term "and/or" means "and" or "or" or both.
As used herein, the term "comprising" as used in this specification means "consisting at least in part of. When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner.
It is intended that reference to a range of numbers disclosed herein (for example, 1 to 10) also incorporates reference to all rational numbers within that range (for example, 1, 1.1, 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9 and 10) and also any range of rational numbers within that range (for example, 2 to 8, 1.5 to 5.5 and 3.1 to 4.7) and, therefore, all sub-ranges of all ranges expressly disclosed herein are hereby expressly disclosed. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner.
The term "therapeutically effective amount", as used herein, means the amount of an active compound, or a material, composition, composition, or dosage form comprising an active compound, which is effective for producing some desired therapeutic or prophylactic effect, commensurate with a reasonable benefit/risk ratio. Therapeutically effective amounts can be determined using routine optimisation techniques well known in the art.
The term "pharmaceutically acceptable" as used herein in conjunction with the terms "salt", "prodrug", or "carrier" refers to compounds of the invention, ingredients, materials and the like, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of a human without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier must also be "acceptable" in the sense of being compatible with the other ingredients of the composition. The term "treatment", and related terms, such as "treating" and "treat" as used herein, in the context of treating a condition, relates generally to treatment of a human, in which some desired therapeutic effect is achieved. The therapeutic effect may, for example, be the inhibition of progress of the condition, including a reduction in the rate of progress; a halt in the rate of progress of the condition; amelioration of the condition; and cure of the condition.
Treatment as a prophylactic measure (i.e., prophylaxis) is also included. Treatment also includes combination treatments and therapies, in which two or more treatments or therapies are used, for example, sequentially or simultaneously, in combination. For example, a therapeutically effective amount of a compound of the invention could be combined with or used in conjunction with a known cannabinoid compound.
The term "cannabinomimetic" as used herein means having similar effects to the effects of cannabis when administered to a subject. The term "alkyl" means a saturated hydrocarbon radical containing normal, secondary, or tertiary carbon atoms. Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1 -butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl- 1-propyl (i- Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl
(-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3 -methyl- 1 -butyl (-CH2CH2CH(CH3)2), 2-methyl- 1- butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl
(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (- CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (- CH(CH3)C(CH3)3, and octyl (-(CH2)7CH3). The term "alkenyl" means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one double bond. Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2). The term "alkynyl" means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one triple bond. Examples of suitable alkynyl groups include, but are not limited to, acetylenic (-C≡CH), propargyl (-CH2C≡CH), and the like.
The term "cycloalkyl" means a hydrocarbon radical containing a saturated ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
The terms "cycloalkenyl" and "cycloalkynyl" have analogous meanings. The term "aryl" means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
The term "alkoxy" means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom. Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy
(-OCH2CH3 or -OEt), t-butoxy (-0-C(CH3)3 or -OtBu) and the like.
The term "halo" as used herein means iodo, bromo, chloro, or fluoro.
The term "haloalkyl" means an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halo group. Examples of suitable haloalkyl groups include, but are not limited to, -(CH2)nF, -CF3, -CHF2, -CFH2, -CH2CF3, and the like.
The terms "haloalkenyl" and "haloalkynyl" have analogous meanings. The term "optionally substituted" in reference to a particular moiety of the compound of the invention (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents.
The term "substituted" in reference to alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl means alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR, where each X is independently halo; and each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci-Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, a C3-Ci2 heterocycle, or a protecting group (PG). When the number of carbon atoms is designated for a substituted group, the number of carbon atoms refers to the group, not the substituent (unless otherwise indicated). For example, a C1-4 substituted alkyl refers to a C1-4 alkyl, which can be substituted with groups having more than the, e.g., 4 carbon atoms.
The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the compound of the invention, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalysed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analogue or latent form of a therapeutically active compound.
One skilled in the art will recognise that substituents and other moieties of the compounds of Formula I should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition. Compounds of the invention which have such stability are contemplated as falling within the scope of the present invention. The term "heteroalkyl" refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S. For example, if the carbon atom of the alkyl group which is attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CH3)2, etc.), or a thioalkyl group (e.g., -SCH3). If a non-terminal
carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH2CH2-O-CH3, etc.), an alkyl amine (e.g., -CH2NHCH3, -CH2N(CH3)2, etc.), or a thioalkyl ether (e.g.,-CH2-S-CH3). If a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g., O, N, or S), the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g., -CH2CH2-SH). A heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. A Ci-C6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
The terms "heterocycle" or "heterocyclyl" as used herein include by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern
Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Chem. Soc. (1960) 82:5566. The terms "heterocycle" and "heterocyclyl" include saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings {i.e., heteroaromatic rings). The terms "heterocycle" and "heterocyclyl" also include substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups. Examples of substituted heterocycles include, but are not limited to, 4,4-difluoro-l-piperidinyl and N-methyl-2-piperidinyl.
The term "heterocycle" or "heterocyclyl" employed alone or in combination with other terms means, unless otherwise stated, a saturated or unsaturated non-aromatic monocyclic heterocyclyl ring or a bicyclic heterocyclyl ring. Monocyclic heterocyclyl rings include monovalent 3-, 4-, 5-, 6-, or 7-membered rings containing one or more heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur in the ring. Monocyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the ring. Examples of monocyclic
heterocyclyl groups include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,
thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiopyranyl, and trithianyl.
Bicyclic heterocyclyl rings include monovalent monocyclic heterocyclyl rings fused to phenyl rings, cycloalkyl rings, or other monocyclic heterocyclyl rings. Bicyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the rings. Examples of bicyclic heterocyclyl groups include, but are not limited to, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3- dihydro- 1 -benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3-dihydro-lH-indolyl, and 1,2,3,4- tetrahydroquinolinyl. In some embodiments the heterocyclyl is monocyclic. "Heteroaryl" refers to an aromatic heterocyclyl. Non-limiting examples of suitable heteroatoms which can be included in the aromatic ring include oxygen, sulphur, and nitrogen. Non-limiting examples of heteroaryl rings include pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.
The term "halogenating agent" includes phosphorous oxychloride, thionyl chloride, oxalyl chloride, phosphorous trichloride, phosphorous pentachloride, and diphosgene.
The term "halogenated solvent" includes chloroform, dichloromethane, and carbon tetrachloride.
The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
"Diastereomer" refers to a stereoisomer with two or more centres of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
5.2 The compounds of the invention
The invention provides cannabinoid compounds that have a range of therapeutic activities including analgesic, anti-inflammatory, and anti-emetic. The compounds of the invention also have psychotropic effects so can be used as relaxants to induce positive mood change.
In one aspect, the present invention provides a compound of formula I,
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-Cg haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-Cg haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula I,
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2SO2, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C20 aryl, C3-C20 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aR12b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cr C8 alkoxy, C6-C20 aryl, C3-C2o cycloalkyl, C1-C20 heteroalkyl, C3-C2o heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C2o aryl, C6-C2o haloaryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, C6-C2o heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20 heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN,
-N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention provides the present invention provides a compound of formula I,
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Y, B, Ri, R2-R5, and R6c are as defined in preceding aspect;
a pharmaceutically acceptable salt or prodrug thereof.
wherein
R6c is cyano; and
Y, B, Ri, and R2-R5 are as defined in the preceding aspect; and
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula I,
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C2o aryl, C3-C20 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -
S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cs alkoxy, C6-C20 aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20 heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cs haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C20 aryl, C6-C20 haloaryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
Ri2a and R^b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged Cg-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
The following embodiments relate to any of the aspects relating to the compound of formula I above, as appropriate.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, or C6-Ci2 aryl, wherein each of said alkyl or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, or C6-C12 aryl.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH, preferably Y is selected from (C=0)0, (C=S)0, S02CH2, S020, S02NH, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH, preferably Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0), CH2(C=0), or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, 0(C=0), CH2(C=0), or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, 0(C=0), CH2(C=0), or NH(C=0).
In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, or (C=0)NH. In one embodiment, Y is selected from (C=0)0 or (C=0)NH. In one embodiment, Y is (C=0)NH.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR,
-C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -
S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Cp
Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Q-Cg alkyl, Q-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -
S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, Ci-Cg cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6
alkylene- C6-C12 aryl, Ci-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, CrC6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
In one embodiment, Ri is selected from C1-C6 alkyl, Ci-C6 bromoalkyl, C1-C6 fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene-3,3-difluoro- l-cyclohexyl, Ci-C6 alkylene-p- fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2-bicyclo[2.2.1]heptanyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl.
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N- piperidinyl).
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene cyclohexyl, methylene-3,3-difluoro- l-cyclohexyl, methylene-p-fluoro-phenyl, methylene- adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2- bicyclo[2.2.1]heptanyl, and methylene-4-tetrahydropyranyl.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl.
In one embodiment, R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, S02, SO3H, NR12aRi2b, S02NR12aRi2b, CONR12aRi2b, halo, d-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, Ci-Cg alkoxy, C6-Ci2 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, or C6-C12 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH,
-S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R2 is hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5 are each independently selected from hydrogen, SO2, NRi2aRi2b> S02NRi2a i2b, CONRi2aRi2b, halo, Ci-C8 alkyl, Ci-Cs alkoxy, wherein each of said alkyl or alkoxy may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C§ heterocycle.
In one embodiment, R2 is hydrogen, S02, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, or CpCs alkyl, wherein each of said alkyl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5 are each independently selected from hydrogen or halo, preferably hydrogen.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring, preferably methyl. In another embodiment, R6a and R6b together form a C3-C6 cycloalkyl ring, preferably cyclopropyl.
In one embodiment, R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
In one embodiment, the heterocyclyl ring is a 5 or 6 membered ring.
In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
In one embodiment, the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
In one embodiment, R6a and R6b are each methyl or R6a and R6b together form a cyclopropyl or cyclopentyl ring.
In one embodiment, R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-Cg haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkyl, C2-Cg alkenyl, C2-C§ alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle. In one embodiment, R6c is cyano.
In one embodiment, R6c is selected from Ci-C8 alkyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said alkyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN,
-N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-Cg alkyl, C2-Cg alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said alkyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -0S(=0)20R, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. In one embodiment, R6c is selected from Ci-C8 alkyl, Ci-C8 haloalkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, or C3-Ci2 heterocyclyl, wherein each of said alkyl, haloalkyl, aryl, haloaryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more -X, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)0R, -C(S)R, -C(0)0R, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -
C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR,
-CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, the Ci-Cs alkylene heterocyclyl is Ci-C6 alkylene heterocyclyl. In one embodiment, the Ci-C6 alkylene heterocyclyl is methylene heterocyclyl. In one embodiment, the heterocyclyl ring is a pyrrolidinyl ring. In one embodiment, the methylene heterocyclyl is methylene pyrrolidinyl, for example methylene-N-pyrrolidinyl.
In one embodiment, the C2-C8 alkynyl is C2-C6 alkynyl. In one embodiment, the C2-C6 alkynyl is ethynyl.
In one embodiment, the C6-Ci2 aryl is phenyl.
In one embodiment, the C6-Ci2 haloaryl is halophenyl. In one embodiment, the halophenyl is chlorophenyl or fluorophenyl.
In one embodiment, R6c is selected from methylene heterocyclyl, C2-C6 alkynyl, phenyl, halophenyl or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo. In one embodiment, R6c is selected from methylene pyrrolidinyl, ethynyl, phenyl, chlorophenyl, fluorophenyl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from Ci-C6 alkyl, Ci-C6 haloalkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, or C3-C12 heterocyclyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from C1-C6 alkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0), CH2(C=0), or NH(C=0);
R6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR,
-C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle; and
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle. In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0);
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, C6-C12 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-Cs heterocycle; and
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C6-Ci2 aryl, C3- C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene- tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, - Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Y is selected from (C=0)0 or (C=0)NH;
R6c is selected from Ci-Cg alkylene heterocyclyl, C2-C8 alkynyl, C6-C12 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -0S(=0)20R, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle; and
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, Ci-Cs cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-C12 aryl, C1-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-Ci2 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S , (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C6-C i2 aryl, C p
C6 alkylene-tetrahydropyranyl, C i-C6 alkylene-3,3-difluoro-l-cyclohexyl, C i-C6 alkylene-p- fluoro-phenyl, C i-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C i-C6 alkylene-cycloheptanyl, C i-C6 alkylene-2-bicyclo[2.2.1]heptanyl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
R2-R5, R6a, Rfti, R6c, Ri2a and Ri2b are as defined above in the second aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B , R2-R5, R6a, 6b, R6c, Ri2a and Ri¾ are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S , (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, C i-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C i-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C i2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are each independently selected from hydrogen or halo;
R6a> R6b> and R6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B , R2-R5, R6a, Rib, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a, 6b, and R6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6 are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R6c is as defined above in the second aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, 6a> R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R6c is selected from C1-C6 alkyl, C6-C12 aryl, C6-Ci2 haloaryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, heterocyclyl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from Ci-C6 alkyl, C6-Cio aryl, C6-C10 haloaryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, 6a, 6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.Ci-C6 alkylene-
In one embodiment, Ri is Ci-Ce alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-
phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.Ci-Ce alkylene- one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C6 alkyl, Ci-Ce bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro- l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, 6b, and R6c are as defined in the preceding embodiment. In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-
piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, 6a> R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In a further aspect, the present invention provides a compound of formula la,
wherein
Yi is selected from O, S, or SO2;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Q-Q alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
Ri2a and R12b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula la,
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONR12aRi2b, COR12a, COORi2a, d-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally
substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R,
-OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o
heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-Cg cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-Cg alkyl, C2-Cg alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged Cg-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention provides the present invention provides a compound of formula la,
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Yi, Y2, B, Ri, R2-R5 and R7-R11 are as defined in the preceding aspect;
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula la,
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-C§ haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R,
-OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NR12aR12b, S02NR12aR12b, CONR12aR12b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, C6-C2o aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20
heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
Ri2a and Ri2 are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
The following embodiments relate to any of the aspects of the compound of formula la above, as appropriate.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, or C6-Ci2 aryl, wherein each of said alkyl or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H,
-S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
In one embodiment, Ri2aand Ri¾ are each independently selected from hydrogen, Ci-Cg alkyl, or C6-C12 aryl.
In one embodiment, Ri2aand Ri¾ are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
In one embodiment, Yi is selected from O, S, or S02> preferably Yi is selected from O or S. In one embodiment, Yi is O.
In one embodiment, Y2 is selected from CH2, O, or NH, preferably Y2 is selected from NH or O. In one embodiment, Yi is O; and Y2 is NH or O. In one embodiment, Yi is O; and Y2 is NH. In one embodiment, B is CH. In one embodiment, B is N.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cs alkyl, C2-Cg alkenyl, C2-Cs alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-Cg haloalkenyl, C2-Cs haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or C1-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -
OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from CONRi2aRi2b> CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR,
-C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle. In one embodiment, Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C12 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R,
-C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-C12 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, Ci-C8 cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-Ci2 aryl, Ci-C6 alkylene- C6-C12 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
In one embodiment, Ri is selected from C1-C6 alkyl, Ci-C6 bromoalkyl, C1-C6 fluoroalkyl, C6-Ci2 aryl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo.
In one embodiment, Ri is C1-C6 alkylene-4,4-difluoro- l-cyclohexyl.
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N- piperidinyl).
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene- 3, 3- difluoro-1 -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N- methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2. l]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl.
In one embodiment, R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-Cg alkynyl, Ci-Cs alkoxy, C6-C12 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3- C12 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy,
aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
In one embodiment, R2 is hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, R7-R11 , X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, R7-R11 , X, and R are as defined in the preceding embodiment. In one embodiment, R2-Rs and R7-R11 are each independently selected from hydrogen, S02, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, C C8 alkyl, d-C8 alkoxy, wherein each of said alkyl or alkoxy may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C§ heterocycle.
In one embodiment, R2 is hydrogen, SO2, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, or CpCs alkyl, wherein each of said alkyl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, R7-R11, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, R7-R11, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5, R7- R11 are each independently selected from hydrogen or halo.
In one embodiment, R2-R5, R7, Rs, Rio, and Rn are hydrogen and R is halo. In one embodiment, R2-R5, R7, Rs, Rio, and Rn are hydrogen and R9 is fluoro.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring. In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring.
In one embodiment, R6a and R6b are each methyl or R6a and R6b together form a cyclopropyl or cyclopentyl ring.
In one embodiment, R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
In one embodiment, the heterocyclyl ring is a 5 or 6 membered ring.
In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
In one embodiment, the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
In one embodiment, R6a and R6b are each independently methyl.
In one embodiment, R6a and R6b together form a cyclopropyl ring. In one embodiment, Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH; and
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-Cs haloalkenyl, C2-Cg haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-C12 aryl, C6-Ci2 fluoroaryl, C6-C12 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Yi is O;
Y2 is selected from NH or O; and
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3- C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene- tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, - Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C 12 fluoroaryl, C6-Ci2 aryl Cp Cg alkyl, C3-C 12 cycloalkyl, bridged C6-C i2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Yi is O;
Y2 is selected from NH; and
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fiuoroalkyl, Ci-Cg cyanoalkyl, C6-C i2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-C 12 aryl, C 1-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C 1-C 10 alkyl, C6-Ci2 aryl, C6-C i2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C 12 cycloalkyl.
In one embodiment, Yi is selected from O or S;
Y2 is selected from CH2, O, or NH; and
B, Ri, R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O; and
B, Ri, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen or halo;
R6a, R6b, and R7-R11 and Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a, 6b, and R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene-
3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, Ci-Cs alkyl, or Ci-C8 alkoxy, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene-
3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen or halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6 are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R IS halo;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rgb together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is C1-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C6 alkyl, C1-C6 bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2-
bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C6 alkyl, Ci-C6 bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C alkylene-cycloheptanyl, Ci-C alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6 together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b> and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-
piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a> R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-
piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R7- Rii are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, the compound of the invention is SGT-23, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-24, or a pharmaceutically acceptable salt or prodrug thereof
In one embodiment, the compound of the invention is SGT-25, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-41, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-42, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-55, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-56, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-60, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-65, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-67, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the com ound of the invention is
pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is
In one embodiment, the compound of the invention is selected from the group comprising: SGT-23, SGT-24, SGT-25, SGT-41, SGT-42, SGT-55, SGT-56, SGT-60, SGT-65, SGT-67, MJ1-MJ12, MJ14, and MJ15, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1, 2, and 3 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1 and 2 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof.
Asymmetric centres may exist in the compounds of the invention. The asymmetric centres may be designated by the symbols "R" or "S", depending on the configuration of substituents in three dimensional space at the chiral carbon atom. All stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1- isomers, and mixtures thereof of the compounds are contemplated herein. Individual enantiomers of the compounds can be prepared synthetically from commercially available enantiopure starting materials or by preparing enantiomeric mixtures of the compounds and resolving the mixture into individual enantiomers. Resolution methods include conversion of the enantiomeric mixture into a mixture of diastereomers and separation of the diastereomers by, for example, recrystallisation or chromatography; direct separation of the enantiomers on chiral chromatographic columns; and any other appropriate method known in the art.
Starting materials of defined stereochemistry may be commercially available or made and resolved by techniques well known in the art.
Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New
York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral centre(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereo specificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
The compounds of the invention may also exist as geometric isomers. All cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as the appropriate mixtures thereof of the compounds are contemplated herein. The compounds may also exist as tautomers, for example, keto/enol; imine/enamine;
amide/imino alcohol; nitroso/oxime; thioketone/enethiol; N- nitroso/hyroxyazo; and nitro/aci- nitro. All tautomeric isomers of the compounds are contemplated herein.
The compounds may also exist as isotopologues and isotopomers, wherein one or more atoms in the compounds are replaced with different isotopes. Suitable isotopes include, for example, 2H (D), 3H (T), 12C, 13C, 14C, 160, and lsO.
The compounds may exist in solvated or unsolvated forms. If the solvent is water, the solvate may be referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, or a tri-hydrate. All solvates of the compounds are contemplated herein.
Pharmaceutically acceptable salts of the compounds of the invention are also contemplated herein. Salts of the compounds include, for example, acid addition salts, base addition salts, and quaternary salts of basic nitrogen-containing groups.
Acid addition salts can be prepared by reacting compounds, in free base form, with inorganic or organic acids. Examples of inorganic acids include, but are not limited to, hydrochloric; hydrobromic; hydroiodic; nitric; carbonic; sulfuric; and phosphoric acid. Examples of organic acids include, but are not limited to, cholic; sorbic; lauric; acetic; trifluoroacetic; formic; propionic; succinic; glycolic; gluconic; digluconic; lactic; malic; tartaric; citric; ascorbic; glucuronic; maleic; fumaric; pyruvic; aspartic; glutamic; aryl carboxylic; anthranilic acid; mesylic; stearic; salicylic; phenylacetic; mandelic; embonic (pamoic); alkylsulfonic; ethanesulfonic; arylsulfonic; benzenesulfonic; pantothenic; sulfanilic;
cyclohexylaminosulfonic; β-hydroxybutyric; galactaric; galacturonic; adipic, alginic; butyric; camphoric; camphor sulfonic; cyclopentanepropionic; dodecylsulfic; glycoheptanoic;
glycerophosphic; heptanoic; hexanoic; nicotinic; 2-naphthalesulfonic; oxalic; palmoic;
pectinic; 3-phenylpropionic; picric; pivalic; thiocyanic; tosylic; and undecanoic acid.
Base addition salt can be prepared by reacting compounds, in free acid form, with inorganic or organic bases. Examples of base addition salts include metal salts and organic salts.
Preferred metal salts include alkali metal salts, alkaline earth metal salts, and other physiologically acceptable metal salts. Preferably the metal salt comprises aluminium, calcium, lithium, magnesium, potassium, sodium, or zinc. Organic salts may be made from amines, such as trimethylamine, diethylamine, N,N-dibenzylethylenediamine,
chloroprocaine, ethanolamine, diethanolamine, ethylenediamine, meglumine (Ν- methylglucamine), and procaine.
5.3 Methods of making the compounds of the invention
The abbreviations used in the general methods are defined as follows: "LG" is an appropriate leaving group and includes halo, tosyl, triflate, mesyl, and any other highly stabilised anionic leaving group. Such leaving groups are known to those of skill in the art.
"ΑΙΒΝ" means azobisisobutyronitrile. "NBS" means N-bromo succinimide. "DCM" means dichloromethane (CH2CI2). "Et" means ethyl. "EtOAc" means ethylacetate. "Me" means methyl (-CH3). "MeOH" means methanol. "MeCN" means acetonitrile. "Pr" means propyl.
"i-Pr" means isopropyl (-CH(CH3)2). "i-PrOH" means isopropanol. "rt" means room temperature. "THF" means tetrahydrofuran. "TLC" means thin layer chromatography.
In the context of the present invention, protecting groups include prodrug moieties and chemical protecting groups.
Protecting groups (PG) are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical PG will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of depro tection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the person skilled in the art. Various functional groups of the compounds of the invention may be protected. For example, PGs for -OH groups (whether hydroxyl, carboxylic acid, phosphonic acid, or other functions) include "ether- or ester-forming groups". Ether- or ester-forming groups are capable of functioning as chemical PGs in the synthetic schemes set forth herein. However, some hydroxyl and thio PGs are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
A very large number of hydroxyl PGs and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471- 16019-9) ("Greene"). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme
Verlag Stuttgart, New York, 1994), which is incorporated by reference in its entirety herein. In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages
155-184. For PGs for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid and other PGs for acids see Greene as set forth below. Such groups include by way of example and not limitation, esters, amides, hydrazides, and the like. Ester-forming groups include: (1) phosphonate ester-forming groups, such as
phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis- amidates; (2) carboxyl ester- forming groups, and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate. The compounds of the invention may be synthesised according to the general methods described below.
General method A Compounds of formula (He) can be prepared using the synthetic route detailed in Scheme 1, in which, Ri, R2-R5, R6a-R6c, Yi, Y2, and B are as defined for the invention and LG is an appropriate leaving group.
Compounds of formula (Ha), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed. For example, many compounds of formula (lib) wherein LG is halo, for example bromo, are commercially available. Alternatively, compounds of (lib) may be prepared from their corresponding alcohols. For example, compounds of formula (lib) wherein LG is, for example, tosyl or mesyl, may be prepared from the corresponding alcohol by reaction with p-toluene sulfonyl chloride or methane sulfonyl chloride and a base such as triethylamine in dichloromethane.
In the first step, a compound of formula (Ila) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C. A solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ila), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes. Suitable reaction conditions would be known to one of skill in the art or could be found in /. Med. Chem. 1991 ; 34(3): 1099- 1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
The compound of formula (lie) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, crystallisation, or preparative HPLC.
In the second step, a solution containing a halogenating agent, such as thionyl chloride, oxalyl chloride, or phosphorous oxychloride, in an anhydrous solvent is added dropwise to a stirred solution of compound (lie) in the same anhydrous solvent at 0°. The resulting mixture is stirred at 0°C for at least 30 minutes, returned to room temperature, and stirred for at least 30 minutes. The mixture is then cooled to 0°C.
A solution containing compound (lid) and a base, such as triethylamine or
disopropylethylamine, in the same anhydrous solvent the mixture containing the acid chloride is added dropwise to the above described mixture, and the mixture is stirred at 0° for at least thirty minutes. The mixture is then warmed to room temperature and stirred for at least 30 minutes. A saturated solution of sodium bicarbonate is then added to the reaction mixture. The compound of formula (He) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
General method B
Compound of formula (He) can also be prepared using the synthetic route detailed in Scheme 1, in which, Ri, R2-R5, R6a-R6c, Yi, Y2, and B are as defined for the invention and LG is an appropriate leaving group may.
The first step of the synthesis is as described above with respect to General method A.
In the second step an activating agent, such as N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU) or Ν,Ν-dicyclohexylcarbodiimide (DCC), is added to a stirred solution of compound (lie) and compound and in dichloromethane at 0°C. The reaction mixture is allowed to warm to room temperature and then stirred for 12 hours. In some embodiments, for example, where the activating agent is HBTU, a base such as diisopropylethylamine is added to reaction mixture following the addition of the activating agent. The order of addition of the reagents may be varied, as appropriate.
Standard work-up and, optionally, purification provide the compound of formula (He). For example, after stirring for 12 hours the reaction mixture is filtered through Celite, concentrated under reduced pressure , and then purified by column chromatorgraphy and then crystallisation from an appropriate solvent or mixture of solvents, for example a mixture of hexane-ethyl acetate. General method C
Compounds of formula (He) can also be prepared using the synthetic route detailed in Scheme IB, in which Rl5 R2-R5, R6a-R6c> Yi, Y2, and B are as defined for the compounds of the invention and LG is an appropriate leaving group.
Scheme 1 B
Compounds of formula (Ha), (lib), and (lid) can either be obtained from commercial suppliers or synthesised according to standard methods known in the art as needed. In the first step, a compound of formula (Ila) is coupled with a compound of formula (lid). The compound of formula (Ila) is treated with a suitable activating agent, for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU), in an ahydrous aprotic organic solvent, typically N,N-dimethylformamide (DMF), at ambient temperature under an atmosphere of argon. Other activating agents may be used, depending on the nature and reactivity of the compound of formula (lib). For example, for certain compounds of formula (lib) wherein one or more of R2-R5 is halo, for example fluoro, N,N- dicyclohexylcarbodiimide (DCC) may be used as the activating agent. A wide range of activating agents are known in the art for activating, for example, carboxylic acid groups for reaction with alcohols and amines.
A base, such as triethylamine or diisopropylamine, is then added dropwise at ambient temperature over suitable period of time, for example 2 hours. The period of time over which the base is added may depend on the scale of the reaction. Depending on the reactivity of the reagents, it may be desirable to cool the reaction mixture prior to and/or during addition of the base.
The reaction mixture is then stirred at ambient temperature for 15 hours before gradually heating to 120°C, for example at 25°C per hour, and then heating at 120°C for 3 hours. The
progress of the reaction may be monitored by any suitable means known in the art, for example thin layer chromatography or HPLC.
Standard workup and, optionally, purification provides the compound of formula (X). For example, as described herein in the Examples, the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then saturated sodium carbonate solution added and resultant mixture cooled to below 5°C to form a precipitate. The precipitate is filtered and washed with water, triturated with saturated sodium carbonate solution, and then filtered and washed again with water. Finally, toluene is added and then evaporated to provide the compound of formula (X).
Alternative, workup and purification methods may be used as appropriate depending on the nature and reactivity of the compound of formula (X). In the second step, the compound of formula (X) is coupled with a compound of formula
(lib) in the presence of a suitable base. For certain compound of formula (X), the reaction is carried out by combining the compound of formula (X) and anhydrous potassium carbonate in a suitable solvent, for example anhydrous DMF, and then adding the compound of formula (lib) at ambient temperature. The reaction mixture is then heated at 70°C for 15 hours.
Standard workup and, optionally, purification provides the compound of formula (He). For example, as described herein in the Examples, the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then ethyl acetate added. The mixture is then poured onto ice and, once the ice has melted, the organic layer separated. The aqueous layer is then extracted with ethyl acetate, and the combined organic extracts washed with sodium carbonate solution, then dried over sodium sulfate and filtered. The solvent is removed, ethyl acetate added and the solution passed through silica. Fractions containing the compound of formula (He) are combined and the solvent removed to provide the desired compound. Other workup and purification methods may be used, as appropriate.
General method D
A compound of formula (IIIc) can be prepared using the synthetic route detailed in Scheme 2, in which, Ri, R2-R5, R6a-R6c> Y2, and B are as defined for the invention, and LG is an appropriate leaving group.
Compounds of formula (Ilia), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed. A compound of formula (Ilia) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C. A solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ilia), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
The compound of formula (Illb) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (Illb). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
A solution containing compound (Illb), AIBN, and NBS in a halogenated solvent and acid is stirred at room temperature for at least five minutes, and then irradiated for at least 4 hours. Water may be added and the mixture extracted with a halogenated solvent.
The compound of formula (IIIc) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, a halogenated solvent and water is added to the reaction mixture containing the compound of formula (IIIc). The aqueous phase is extracted with a halogenated solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
The compounds of the invention may also be synthesised according to the schemes described below using the techniques set out in general methods A and B and using reaction conditions known to those of skill in the art. In the schemes below, Ri, R2-R5, R6a-R6c, PG, and B are as defined for the invention, and LG is an appropriate leaving group.
A person skilled in the art, understanding the disclosures of the general methods and specific preparation examples, would know how to modify the general methods to accommodate the different substituents that may be present on the compounds of the invention.
The embodiments of the invention described above are intended to be merely exemplary, and those skilled in the art will recognise, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific materials, compounds, and procedures. All such equivalents are considered to be within the scope of the invention as set out in the accompanying claims
5.4 Pharmaceutical compositions
The compounds of the invention can be used in a range of medicinal applications. While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical compositions. The compositions of the invention comprise one or more compounds of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients. The carriers must be "acceptable" in the sense of being compatible with the other ingredients of the composition and physiologically innocuous to the recipient. The carrier must also be suitable for the mode of administration of the active agent.
In one aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a
pharmaceutically acceptable carrier. Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, gel, caps, tablets, troches, lozenges, aqueous or oil
suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents including sweetening agents, flavouring agents, colouring agents and preserving agents, in order to provide a palatable preparation.
The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain carriers, excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All compositions will optionally contain excipients such as those set forth in the
Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety. Carriers and excipients include methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from about 3 to about 11, but is ordinarily about 7 to 10.
The compound of the invention may exist in a suspension. Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, such as sucrose or saccharin.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth herein, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
The oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of cream compositions.
Emulgents and emulsion stabilisers suitable for use in the composition of the invention include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate. Oral compositions
In one embodiment, the composition of the invention is an oral composition. Preferably, the composition is in the form of a pill, tablet, or dragee. A tablet is made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active
ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable carrier, which is suitable for manufacture of tablets. These carriers may be, for example, inert diluents, such as 2-hydroxypropyl beta-cyclodextrin, methylsulfonylmethane (MSM), mannitol, calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatine or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including
microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed. In one embodiment, the composition of the invention comprises methylsulfonylmethane (MSM) as the carrier. In one embodiment, the composition of the invention comprises 2- hydroxypropyl beta-cyclodextrin as the carrier. Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules (gel caps), cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.
Compositions for oral use may be also presented as hard gelatine capsules (gel caps) where the active ingredient is mixed with an inert solid carrier, for example methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
In one aspect, the invention provides a pharmaceutical composition for oral administration. In one embodiment, an oral pharmaceutical composition of the invention is prepared as follows: a compound of the invention is dissolved in a solvent, such as acetone or diethyl
ether, and is mixed with a suitable diluent at a ratio of active ingredient:diluent of 1:99. Suitable diluents include those that are approved for use in food, dietary supplements, or tabletting, and may include 2-hydroxypropyl beta-cyclodextrin, mannitol or
methylsulfonylmethane, more preferably methylsulfonylmethane. Optional carriers and/or excipients may also be added. The solvent may then be removed.
The resulting powder may be then divided up into capsules or pressed into tablets.
Inhalable compositions
The compounds are of the invention are also absorbed when administered by inhalation. In one embodiment, the composition of the invention is a nasal, e-liquid, or vaporiser composition. Compositions suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 μηι (including particle sizes in a range between 0.1 and 500 μιη in increments such as 0.5 μιη, 1 μιη, 30 μιη, 35 μιτι, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable compositions include aqueous or oily solutions of the active ingredient. Compositions suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other suitable therapeutic agents.
In one aspect, the invention provides an inhalable composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, an inhalable composition of the invention is prepared as follows: a compound of the invention is dissolved in a solution of water and propylene glycol, and optionally a surfactant, a fungicide, and/or a bacteriostatic agent. Preferably, the ratio of propylene glycohwater may be in the range of 0.5: 10 to 3: 10, preferably 1.5: 10. Preferably, the ratio of surfactant:water may be in the range of 0.001: 10 to 0.5:10, preferably 0.05:10. Preferably, the surfactant, if present, may be Tween 20.
A compound of the invention is dissolved initially in propylene glycol with stirring.
Optionally, a surfactant, a fungicide, and/or a bacteriostatic agent is then added followed by water. Preferably, the mixture is heated with stirring to ensure the compound of the invention dissolves into solution. After cooling, the mixture is administered nasally.
An e-cigarette is an electronic inhaler that vaporises a liquid solution (e-liquid) into an aerosol mist, simulating the act of tobacco smoking. In one aspect, the invention provides an e-liquid comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the e-liquid is a mixture of propylene glycol and glycerine, preferably vegetable glycerine. In one embodiment, the e-liquid has a preferred ratio of propylene glycokglycerine may be from 1:1 to 4: 1, more preferably 3:2. In one embodiment, the e-liquid further comprises a flavour enhancer, such as Tasty Puff or similar.
In one embodiment, the e-liquid optionally includes a surfactant to enhance solubility. The surfactant may be present at a concentration of between 0.01% and 5% by weight, more preferably 0.5% by weight. The surfactant may be chosen from the group consisting of Triton X- 100, Tween 20 and Tween 60, more preferably Tween 20.
In one embodiment, an e-liquid of the invention may be prepared as follows: the compound of the invention is dissolved in propylene glycol, which may be at room temperature or heated. Preferably, the propylene glycol is heated to 60-90 °C, preferably 80 0 C, with stirring until the compound of the invention is in solution.
Vegetable glycerine, and optionally a surfactant, is added with stirring, and the mixture is allowed to slowly return to room temperature. The mixture may be filtered. A smoking composition is intended to be smoked in a cigarette or pipe.
In one aspect, the invention provides a smoking composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, a smoking composition of the invention is prepared as follows: the compound of the invention is dissolved in acetone and then mixed with a base herb in a large mixing machine.
The base herb is selected from damiana, marshmallow, mugwort, passionflower, lion's tail, blue lotus, calea zacatechichi and salvia divinorum, more preferably damiana. Optionally, food colours are added to the acetone solution to colour the final product. The mixture is mixed for approximately 30-60 minutes, preferably approximately 40 minutes to ensure even distribution of the compound of the invention through the base herb.
The wet mixture is dried to remove the acetone. The dry mixture is then ready for packing and use.
Optionally, the dry mixture is sprayed with flavouring agents, which are dissolved in a propylene glycol and/or ethanol base. Preferably, the mixture is mixed in a mixing machine after being sprayed with a flavouring agent, and then dried for approximately 30 minutes before packing and use.
A preferred blend contains 500g of the compound of the invention and 1kg of powdered food colour (e.g. Brilliant Blue) dissolved in 6 litres of acetone sprayed onto 25kg of damiana. The mixture is then dried over a 12 hour period before being sprayed with 2.5 litres of "Tasty Puff flavour liquid.
The blend may be smoked or used in a vaporiser. Topical compositions The compounds of the invention may be administered topically, for example in a cream. In one embodiment, the composition of the invention is a topical composition. Preferably, the composition is in the form of an ointment, cream, eye drop, or paste.
The choice of suitable oils or fats for a topical composition is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as
Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used. If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical compositions may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogues.
Compositions suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such compositions in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
For administration to the eye or other external tissues e.g., mouth and skin, the compositions are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.
Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerine, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. In one embodiment, the composition of the invention is an oral topical composition, preferably the composition is in the form of a lozenge.
Injectable compositions
The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilised powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
In one embodiment, the composition of the invention is an injectable composition.
Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
Other compositions of the invention
Compositions for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Controlled release compositions of the invention
Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile
of the active ingredient. Accordingly, the invention also provides compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
In one embodiment, the composition of the invention is a time-release composition.
The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release composition intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per millilitre (ml) of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
Unit dosage forms of the compositions of the invention
The pharmaceutical compositions of the invention include those suitable for the foregoing administration routes. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The compositions are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage compositions are
those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients provided by the present invention the compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example those suitable for oral
administration may include flavouring agents.
Dosages of the compound of the invention
The effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies. The effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 0.01 mg to 1000 mg, or between 0.05 mg and 500 mg, and may take the form of single or multiple doses.
In one embodiment, the composition of the invention is in a dosage form which contains at least 0.001 mg of the compound of the invention, preferably 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, or 500 mg of the compound of the invention.
In one embodiment, the composition of the invention is in a dosage form which contains 0.001-500 mg of the compound of the invention, preferably 0.005-500, 0.01-500, 0.05-500, 0.1-500, 0.2-500, 0.3-500, 0.4-500, 0.5-500, 0.6-500, 0.7-500, 0.8-500, 0.9-500, 1-500, 2- 500, 3-500, 4-500, 5-500, 6-500, 7-500, 8-500, 9-500, 10-500, 15-500, 20-500, 25-500, 30- 500, 35-500, 40-500, 45-500, 50-500, 60-500, 75-500, 80-500, 85-500, 90-500, 95-500, 100- 500, 110-500, 120-500, 130-500, 140-500, 150-500, 150-500, 160-500, 170-500, 180-500,
190-500, 200-500, 250-500, 300-500, 350-500, 400-500, or 450-500 mg of the compound of the invention.
In one embodiment, the dosage form is in an inhalable, topical, oral, smokable, or injectable dosage form.
In one embodiment, the composition of the invention is an e-liquid which contains at least 0.1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/ml of the compound of the invention.
In one embodiment, the composition of the invention is an e-liquid which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5- 200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120- 200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/ml of the compound of the invention.
In one embodiment, the composition of the invention is a smoking composition which contains at least 0.1 mg/g of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
In one embodiment, the composition of the invention is smoking composition which contains 0.1-200 mg/g of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4- 200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40- 200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/g of the compound of the invention.
In one embodiment, the composition of the invention is an inhalable composition which contains at least 1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
In one embodiment, the composition of the invention is an inhalable composition which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190- 200 mg/ml of the compound of the invention.
5.5 Uses of the compounds of the invention The compounds of the invention bind to CBi and/or CB2 receptors. Compounds that bind to these receptors are known to have gastrointestinal, cardiovascular, and/or central nervous system activity.
In one embodiment, the compound of the invention is a CBi and/or CB2 receptor agonist.
In one embodiment, the EC50 of the compound of the invention in a CBi and/or CB2 receptor affinity assay is less than about 1000 μΜ, 500 μΜ, 250 μΜ, 100 μΜ, 50 μΜ, 25 μΜ, 10 μΜ, 5 μΜ, 3 μΜ, 1 μΜ, 750 ηΜ, 500 ηΜ, 400 ηΜ, 300 ηΜ, 200 ηΜ, 100 ηΜ, 90 ηΜ, 80 ηΜ, 70 ηΜ, 60 ηΜ, 50 ηΜ, 40 ηΜ, 20 ηΜ, 10 ηΜ, 9 ηΜ, 8 ηΜ, 7 ηΜ, 6 ηΜ, 5 ηΜ, 4 ηΜ, 3 ηΜ, 2 nM, 1 ηΜ, 0.9 ηΜ, 0.8 ηΜ, 0.7 ηΜ, 0.6 ηΜ, 0.5 ηΜ, 0.4 ηΜ, 0.3 ηΜ, 0.2 ηΜ, 0.1 ηΜ, 0.05 ηΜ, 0.01 ηΜ, 0.001 nM, or 0.0001 nM, and useful ranges may be selected between any of these values.
In one embodiment, the EC50 is from about 0.0001 nM to about 1000 μΜ, from about 0.0001 nM to about 100 μΜ, from about 0.0001 to about 10 μΜ, from about 0.001 nM to about 500 μΜ, from about 0.001 nM to about 100 μΜ, from about 0.001 nM to about 50 μΜ, from about 0.001 nM to about 10 μΜ, from about 0.001 nM to about 5 μΜ, from about 0.01 nM to about 500 μΜ, from about 0.01 nM to about 100 μΜ, from about 0.01 nM to about 50 μΜ, from about 0.01 nM to about 10 μΜ, from about 0.01 nM to about 5 μΜ, from about 0.05 nM to about 500 μΜ, from about 0.05 nM to about 100 μΜ, from about 0.05 nM to about 50 μΜ, from about 0.05 nM to about 10 μΜ, or from about 0.05 nM to about 5 μΜ.
In one embodiment, the CBi and/or CB2 receptor affinity assay measures the effect of the compound on cAMP modulation using the HTRF detection method. In one embodiment, the CBi and/or CB2 receptor affinity assay is substantially as described herein in the Examples. The inventors have advantageously found that certain compounds of formula (I) exhibit selective affinity for CBi and/or CB2.
In one embodiment, the compound of the invention is a selective CBi and/or CB2 receptor agonist.
In one embodiment, the compound of the invention is selective for CBi and/or CB2 over at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS 1, opioid μ, opioid δ, opioid K, opioid NOP, prostaglandin EP4, serotonin 5-HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPACl, vasopressin VIA, Ca2+ channel L, V channel, SKCa channel, Na+ channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter. In one embodiment, the compounds are selective for CBi and/or CB2 over all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
In one embodiment, the compounds is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, or 10000 times more selective for CBi and/or CB2 than for the G-protein coupled receptor or ligand-gated ion channel.
Selectivity may be measured by any suitable method known in the art, for example by comparing the Ki or EC50 of the compound for CBi and/or CB2 with the Ki or EC50 of the compound for the G-protein coupled receptor or ligand-gated ion channel. In one embodiment, the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic al, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (non- selective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS1, opioid μ, opioid δ, opioid κ, opioid NOP, prostaglandin EP4, serotonin 5- HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPAC1, vasopressin VIA, Ca2+ channel L, KV channel, SKCa channel, Na+ channel (site 2), Cl- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter.
In one embodiment, the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
In one embodiment, the inhibition of control specific binding and/or control specific binding is measured using a reference radioligand for each G-protein coupled receptor and ligand- gated ion channel.
In one embodiment, the reference radioligand is as defined in Table 6 below.
In one aspect, the invention relates to a use of a compound of the invention in the
manufacture of a medicament for treating pain in a subject.
In another aspect, the invention related to use of a compound of the invention in the manufacture for treating nausea and/or emesis in a subject. In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for stimulating appetite in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a euphoric effect in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for relaxing a subject in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a positive mood change in a subject.
In another aspect, the invention relates to a method of treating pain in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a method for treating nausea and/or emesis in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. In another aspect, the invention relates to a method for stimulating appetite in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a method of inducing a euphoric effect in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a method of relaxing a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. In another aspect, the invention relates to method of inducing a positive mood change in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a compound of the invention for use in treating pain in a subject.
In another aspect, the invention relates to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
In another aspect, the invention relates to a compound of the invention for use in relaxing a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a positive mood change in a subject.
In the above aspects:
In one embodiment, the nausea and/or emesis is caused by injury, pain, cancer, AIDS, tuberculosis, glaucoma, menstruation, hepatitis, chemotherapy, radiotherapy, or headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches).
In one embodiment, the appetite is stimulated to treat loss of appetite caused by wasting. Preferably, the wasting is caused by cystic fibrosis, anorexia, old age, cancer, AIDS, tuberculosis, chronic diarrhoea, or cachexia, preferably cancer cachexia. In one embodiment, the pain is selected from nociceptive pain, neuropathic pain, or psychogenic pain. In one embodiment, the nociceptive pain is caused by: inflammation, joint pain (such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury), headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches), back pain (such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural deformities (such as scoliosis, kephosis, or lordosis)), fibromyalgia, surgery, or trauma. In one embodiment, the neuropathic pain is caused by: multiple sclerosis, phantom limb pain, peripheral (diabetic) neuropathy, post-mastectomy pain, sciatica, spinal cord injury (such as bulging or slipped discs or trauma), carpel tunnel syndrome, cancer, radiotherapy, chemotherapy, radiation injury, surgery, or HIV- associated peripheral neuropathy. In one embodiment, the psychogenic pain is caused by: headache, muscle pain, back pain, or stomach pain. In one embodiment, the pain is atypical or neuropathic pain. In one embodiment, the pain is phantom limb pain. One or more compounds of the invention (herein also referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example the condition of the recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
Although the present invention is broadly as defined above, those persons skilled in the art will appreciate that the invention is not limited thereto and that the invention also includes embodiments of which the following description gives examples.
6. EXAMPLES
Compounds of the invention
SGT-24 was synthesised according to Scheme 1 (as shown above). l-Pentyl-lH-indazole-3-carboxylic acid (lie) was prepared by reaction of commercially available indazole-3-carboxylic acid (Ila) with 1-bromopentane (lib) in the presence of sodium hydride in dimethylformamide. Reaction conditions were as set out in J. Med. Chem. 1991; 34(3): 1099-1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
Oxalyl dichloride (5.74 g, 45.2 mmol) was slowly added to a stirred solution of 1-pentyl-lH- indazole-3-carboxylic acid (10.0 g, 43.0 mmol) in dichloromethane (100 mL) at 0°C in an ice-bath. The reaction was stirred for 30 minutes. Triethylamine (9.0 mL, 64.58 mmol) was then added, followed by 2-phenylpropan-2-amine (5.82g, 43.0 mmol). The reaction was stirred for 1 hour and monitored by TLC. The reaction was diluted with water and separated into phases. The organic layer was washed with water (2x100 mL), brine (2x100 mL), dried (MgS04), and concentrated. The resulting oil was purified by flash column chromatography using petroleum ethenethyl acetate 60: 1 as eluent. 11.7 g (78%) of SGT-24 was obtained as a light yellow oil in a 78% yield. lH NMR (400 MHz, DMSO-d6) δ 8.01 (1H, d, HI), 7.97 (1H, s, H5), 7.74 (1H, d, H4), 7.43 (1H, ddd, H2), 7.38 (1H, dd, H3), 7.19 (2H, m, H7), 4.48 (2H, t, H8), 1.90 (2H, m, Hl l), 1.74 (6H, m, H6), 1.25 (6H, m, H12, H10, H13), and 0.84 (3H, t, H14). MS (ESI+) m/z 350 (MH+).
SGT-42 was synthesised according to Scheme IB (as shown above). N-( 1 -Methyl- 1 -phenylethyl)- lH-indazole-3-carboxamide lH-Indazole-3-carboxylic acid (100 g, 0.617 mol, 1.0 molar eq.) in anhydrous N V- dimethylformamide (DMF)(10 volumes, 1 L) was mixed with cumylamine (89 mL, 1.0 molar eq.) and HBTU (281 g, 1.2 molar eq.) at room temperature under argon. To this mixture was added N,N-diisopropylethylamine (215 mL, 2.0 molar eq.) drop wise over a period of at least 2 hours. The reaction mixture was then stirred for at least 15 hours at ambient temperature under an argon blanket. The reaction mixture was the gradually heated in increments of 25 °C per hour up to an internal temperature of 120°C. Once the reaction mixture reached 120°C, it was continuously heated at an internal temperature of 120°C for at least 3 hours. The reaction mixture was rotary evaporated to remove the DMF that a bath temperature of 80°C under reduced pressure. The crude product was placed in an ice bath and mixed with saturated sodium carbonate solution (10 volumes, 1 L). The resultant mixture was continuously stirred and the ice bath until the internal temperature dropped below 5°C. A beige coloured precipitate formed that was filtered and washed with cold purified water (10 x 2.5 volumes, 10 x 250 mL). The wet filter cake was then triturated in saturated sodium carbonate solution (5 volumes, 500 mL) for at least one hour at room temperature. The suspension was then filtered and rinsed with purified water (5 1 volume, 5 x 100 mL). The resultant product was dried under air vacuum, and then co-evaporated with toluene four times prior to final drying on a rotary evaporator with a bath temperature of 60°C to constant weight.
N-( 1 -Methyl- 1 -phenylethyl)- 1 -r(tetrahydro-2H-pyran-4-yl)methyll- lH-indazole-3- carboxamide (SGT-42)
The quantity of reagents and materials used in the following procedure were based on the quantity of N-(l-Methyl-l-phenylethyl)-lH-indazole-3-carboxamide obtained in the preceding step, as indicated. A solution of N-(l -methyl- l-phenylethyl)-lH-indazole-3-carboxamide (1.0 molar eq.) in anhydrous DMF (5 volumes) was mixed with anhydrous potassium carbonate (5.84 molar eq.). (Tetrahydro-2H-pyran-4-yl) methyl 4-methylbenzenesulfonate (1 molar eq.) was added portion wise over a period of 5 minutes at ambient temperature to the reaction mixture. The resulting reaction mixture was heated to 70°C for at least 15 hours using an oil bath. The reaction mixture was evaporated at a 40°C bath temperature under reduced pressure to remove the DMF. The evaporated residue was mixed with ethyl acetate (5 volumes) and then poured into ice (5 weight equivalents). The mixture was stirred until the ice melted. The bilayer was separated and the aqueous layer extracted with ethyl acetate (4 x 3 volumes). The combined extracts were washed with 50% saturated sodium carbonate solution (4 x 1 volume), then dried over sodium sulfate and filtered. The filtrate was evaporated at a 40° bath temperature and co-evaporated with ethyl acetate (3 x 2.5 volumes). The resultant residue was redissolved and hot ethyl acetate (4 volumes) and filtered through 60 angstrom silica (2.5 volumes) topped with a layer of anhydrous sodium sulphate. The filter bed was washed with hot ethyl acetate (2 volumes per fraction) until all of the product was released. Product containing fractions were evaporated with a bath temperature of 40°C. The crude product was triturated with methyl tert-butyl ether (MTBE)(2 volumes) at room temperature of the 2 hours, and then in an ice bath for one hour. The suspension was filtered, then rinsed with cold MTBE (4 x 1 volume). The resulting white solid was then dried under vacuum to constant weight, mp 112.7 ± 0.5 . IR vmax/cm_1 3328, 1664 (amide). lU NMR (400 MHz, DMSO-d6) δ 8.03 (1H, d, HI), 7.97 (1H, s, H5), 7.82 (1H, d, H4), 7.41-7.44 (3H, m, H2, H3), 7.33 (2H, dt, H8), 7.20 (2H, dd, H7), 4.41 (2H, d, H10), 3.84 (2H, d, H13), 3.25 (2H, m, H14), 2.23 (1H, m, H15), 1.74 (6H , s, H6), and 1.39 (4H, m, Hl l, H12). MS (ESI+) m/z 378 (MH+). Anal. Calcd for C23H27N3O2: C, 73.18; H, 7.21; N, 11.13. Found: C, 73.44; H, 7.22; N, 11.23.
1 13
H and i3C NMR scans for SGT-42 are provided in Figures 1 and 2, respectivley.
SGT 174 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha)
An indole-3-carboxylic acid or indazole-3-carboxylic acid (IIa)(0.1 mol) was dissolved in DMF (100 ml), and treated with NaH (0.2 mol) at 0°C. RxBr (IIb)(0.15 mol) was added in one portion and the mixture stirred at 0°C for 1 hour. Ice water was added, and the mixture extracted with CH2CI2 (3x100 ml). The combined organic extracts were dried over MgS04 and concentrated under vacuum. Crystallisation from EtOAc/Hexane gave the desired 1- alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) as solid.
Formation of amide (He)
The l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (IIc)(1.0 mmol) and amine (IId)(1.0 mmol) were dissolved in CH2CI2 (5 ml). The mixture was cooled with ice- water. DCC (1.0 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature and then stirred over night. The reaction mixture was then filtered through celite and the filtrate concentrated under vacuum. The resultant residue was purified by column chromatography. Crystallization from EtOAc/Hexane gave pure (He).
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.90 (m, 1H), 7.41-7.27 (m, 6H), 7.15 (m, 1H), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
SGT-211
SGT 211 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha) to provide the desired l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) was carried out according to the general procedure described above for SGT 174.
Formation of ester (He)
The l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (IIc)(1.0 mmol) and alcohol (IId)(1.0 mmol) were dissolved in acetonitrile (5 ml). The mixture was cooled with ice-water. DCC (1.0 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature and then stirred over night. The reaction mixture was then filtered through celite and the filtrate concentrated under vacuum. The resultant residue was purified by column chromatography. Crystallization from EtOAc/Hexane gave pure (He). lH NMR (400 MHz, DMSO-d6) δ 7.92 (m, 1H), 7.90 (m, 1H), 7.72 (m, 3H), 7.66 (s, 1H), 7.40 (m, 2H), 7.38 (m, 2H), 4.36 (m, 1H), 4.15 (m, 2H), 1.82 (s, 6H), 1.45-1.27 (m, 11H).
Compounds of formula I of the invention as shown in Table 1 and compounds of formula la were synthesised in an analogous fashion according to the general methods described herein. The aforementioned preparative procedures are representative of the procedures used.
Table 2.
Characterisation data
XH NMR for selected compounds of the invention is as shown below. MS data
provided for selected compounds.
SGT-25
1H NMR (400 MHz, DMSO-d6) δ 8.07 (IH, d, HI), 7.99 (IH, s, H5), 7.92 (IH, d, H4),7.72 (3H, s, H2), 7.40 (2H,s, H3), 7.38 (2H, dt, H), 4.46 (IH, m, H10), 4.31 (2H, s, H14), 2.00- 1.39 (12H, m, H10, Hl l, H12, H13)
SGT-41
lH NMR (400 MHz, CDC13) δ 8.48 (IH, d, HI), 7.45 (2H, d, H5), 7.41-7.35 (5H, m, H2, H3, H4), 7.22 (2H, m, H7), 4.28 (2H, d, Hl l), 1.80 (6H, s, H6), and 1.75-0.75 (12H, m, Hl l, H12, H13, H14, H15, H16). MS m/z 376 (MH+).
SGT-55
lH NMR (400 MHz, DMSO-d6) δ 8.07 (IH, s, H14), 7.97 (IH, d, HI), 7.52 (IH, s, H5), 7.41 (IH, d, H2), 7.38 (2H,s, H3), 7.24 (2H, dt, H8), 7.12 (2H, dd, H7), 7.06 (IH, t, H9), 4.18 (2H, t, H10), 1.77 (2H, m, Hl l), 1.65 (6H, s, H6), 1.28 (2H, m, H12), and 0.89 (H3, t, H13). MS (ESI+) m/z 335 (MH+).
SGT-56
XH NMR (400 MHz, DMSO-d6) δ 8.22 (IH, s, H15), 7.99 (IH, d, H4), 7.52 (IH, s, H5), 7.49 (IH, d, HI), 7.38 (IH, d, H3), 7.34 (2H, t, H2), 7.12 (2H, dd, H7), 7.06 (IH, t, H9), 4.17 (2H, t, H10), 1.77 (2H, m, Hl l), 1.65 (6H, s, H6), 1.31 (4H, m, H12, H13), and 0.90 (H3, t, H14).
SGT-60
1H NMR (400 MHz, DMSO-d6) δ 8.07 (IH, d, HI), 7.98 (IH, s, HI), 7.52 (IH, d, H5), 7.41 (IH, d, H4), 7.38 (lH,s, H3), 7.42 (2H, dt, H2), 7.20 (IH, dd, H7), 4.48 (2H, t, H9), 1.85 (2H, q, Hl l), 1.70 (6H, s, H6), 1.30-1.23 (4H, m, H12), and 0.84 (H3, t, H13).
XH NMR (400 MHz, DMSO-d6) δ 8.01 (dd, =6.0, 1.2Hz, IH), 7.96 (s, IH), 7.73 (dd, =6.0, 1.2Hz, IH), 7.44 (m, IH), 7.39 (m, IH), 7.18 (m, 2H), 4.47 (m, 2H), 1.90 (m, 2H), 1.74 (s, 6H), 1.25 (m, 4H), 0.84 (t, 3H)
1H NMR (400 MHz, DMSO-d6) δ 7.90 (m, IH), 7.68 (s, IH), 7.45 (m, IH), 7.27 (m, 1 7.38 (m, IH), 7.42 (m, 2H), 7.20 (m, 2H), 4,50 (m, IH), 4.36 (m, IH), 4.12 (m, 2H), 1.
2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
XH NMR (400 MHz, DMSO-d6) δ 8.17 (dd, /=6.0, 1.2Hz, IH), 7.98 (s, IH), 7.52 (m, IH), 7.41 (m, IH), 7.38 (m, IH), 7.42 (m, 2H), 7.20 (m, IH), 4,50 (m, IH), 4.40 (m, 3H), 1.85 (m, 2H), 1.70 (s, 6H), 1.70-1.50 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.36 (m, IH), 4.15 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
SGT-78
*H NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,50 (m, 2H). 1.87 (m, 2H), 1.74 (m, 2H), 1.66 (m, 2H), 1.70 (s, 6H).
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, 2H), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.71 (m, 2H). 3.54 (m, IH), 1.82 (s, 6H), 1.69-1.11 (m, 10H).
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, 2H), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 5.60 (m, 2H), 1.82 (s, 6H), 1.69 (s, 9H).
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.69 (m, 2H), 0.94 (s, 9H).
!H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.21 (m, 2H), 7.20 (m, IH), 7.12 (m, 2H), 5.51 (m, 2H), 1.82 (s, 6H).
SGT-150
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 2.51 (m, 2H), 2.26 (s, 3H), 2.22 (m, IH), 1.82 (s, 6H), 1.69-1.47 (m, 6H).
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.50 (m, 2H), 2.13 (m, IH), 1.88 (m, IH), 1.82 (s, 6H), 1.58-1.40 (m, 9H).
XH NMR (400 MHz, DMSO-d6) δ 7.88 (m, IH), 7.69 (s, IH), 7.41 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4.11 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.32 (m, 4H), 0.88 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 7.90 (m, IH), 7.68 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4,49 (m, IH), 4.35 (m, IH), 4.13 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
XH NMR (400 MHz, DMSO-d6) δ 7.89 (m, IH), 7.65 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.25 (s, IH), 3.95 (m, 2H), 1.82 (s, 6H), 1.80 (m, IH), 1.70-1.50 (m, 5H), 1.15 (m, 3H), 1.00 (m, 2H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 3.95 (m, 2H), 1.82 (s, 6H), 1.80 (m, IH), 1 (m, 5H), 1.15 (m, 3H), 1.00 (m, 2H).
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.38 (m, 2H), 1.95 (m, 2H), 1.83 (s, 6H), 1.35 (m, 5H).
1H NMR (400 MHz, DMSO-d6) δ 8.30 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.50 (m, IH), 4.39 (m, 3H), 2.00 (m, 2H), 1.83 (s, 6H), 1.75 (m, 2H), 1.50 (m, 2H). SGT-159
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.20 (m, 2H), 2.03 (m, IH), 1.83 (s, 6H), 1.75-1.50 (m, 5H), 1.25-1.00 (m, 5H).
XH NMR (400 MHz, DMSO-d6) δ 8.31 (m. IH), 8.04 (s, IH), 7.92 (m. IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31- 1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
lR NMR (400 MHz, DMSO-d6) δ 7.92 (m. IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H). 7.38 (m, 2H), 6.25 (s, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
1H NMR (400 MHz, DMSO-d6) δ 8.33 (m, IH), 8.00 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,48 (m, IH), 4.36 (m, IH), 4.15 (m, 2H), 1.75 (m, 2H), 1.50 (m, 2H), 1.29 (m, 2H), 0.85 (m, 2H), 0.60 (m, 2H).
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.45-1.27 (m, 11H), 0.85 (m, 2H), 0.60 (m, 2H).
1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 8.01 (s, IH), 7.84 (m, IH), 7.70 (m, IH), 7.37-7.27 (m, 5H), 7.14 (m, IH), 4.31 (m, 2H), 1.81 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 8.00 (s, IH), 7.90 (m, IH), 7.69 (m, IH), 7.41 (m, 2H), 7.24 (m, 2H), 7.15 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
lH NMR (400 MHz, DMSO-d6) δ 8.35 (s, IH), 8.00 (s, IH), 7.84 (m, IH), 7.69 (m, IH), 7.37-7.27 (m, 5H), 7.15 (m, IH), 4.31 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
SGT-182
1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 7.90 (m, IH), 7.41 (m, 2H), 7.31 (m, IH), 7.24 (m, 2H), 7.15 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 7.90 (m, IH), 7.37-7.27 (m, 6H), 7.15 (m, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
!H NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 3.75 (m, 2H), 3.65 (m, 4H), 2.36 (m, 4H), 1.83 (s, 6H).
lR NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.60 (m, 2H), 0.87 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.69- 1.24 (m, 8H), 0.87 (m, 3H).
SGT- 187
!H NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH). 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.69-1.24 (m, 10H), 0.88 (m, 3H).
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.47 (m, IH), 3.65-3.55 (m, 4H), 1.83 (s, 6H), 1.69-1.44 (m, 5H).
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4.47 (m, IH), 3.65-3.55 (m, 4H), 1.83 (s, 6H), 1.69-1.44 (m, 5H).
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.43 (m, 2H), 7.39 (m, 2H), 7.37 (s, IH), 7.29 (m, 2H), 7.26 (s, IH), 7.21 (m, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69- 1.44 (m, 5H).
XH NMR (400 MHz. DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (s, IH), 7.66 (m, 2H), 7.40 (m, 2H), 7.38 (m, 2H), 6.26 (s, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.69-1.44 (m, 5H), 0.85 (m, 2H), 0.60 (m, 2H).
XH NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.69-1.44 (m, 5H), 0.85 (m, 2H), 0.60 (m, 2H).
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.17 (m, 2H), 1.77 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H)
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.48 (m, IH), 4.36 (m, IH), 4.15 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
SGT-212
!H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4,50 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69-1.44 (m, 5H).
!H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.48 (m, 2H), 1.85 (m, 2H), 1.70 (s, 6H). 1.30-1.23 (m, 4H), 0.84 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4,50 (m, IH), 4.40 (m, 3H), 1.85 (m, 2H), 1.70 (s, 6H), 1.70- 1.50 (m, 4H).
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.93 (m, IH), 7.64 (m, IH), 7.44 (m, IH), 7.42 (m, 2H), 7.37 (m, 2H), 7.21 (m, IH), 4,50 (m, 2H), 1.70 (s, 6H), 1.69-1.27 (m, 11H).
1H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,50 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69-1.44 (m, 5H).
XH NMR (400 MHz, DMSO-d6) δ 7.89 (m, IH), 7.68 (s, IH), 7.60 (s, IH), 7.43 (m, IH), 7.33 (m, 2H), 4,45 (m, 2H), 3.26 (s, IH), 1.74 (m, 2H), 1.70 (s, 6H), 1.30 (m, 4H), 0.89 (m, 3H).
XH NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.68 (s, IH), 7.56 (s, IH), 7.41 (m, IH), 7.28 (m, 2H), 4.46 (m, IH), 4.376 (m, IH), 4.14 (m, 2H), 3.27 (s, IH), 1,75 (m, 2H), 1.59 (s, 6H), 1.49 (m, 2H), 1.29 (m, 2H) .
XH NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.68 (s, IH), 7.60 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.45 (m, 2H), 3.26 (s, IH), 1.70 (s, 6H), 1.69-1.27 (m, 9H).
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4, 1 (m, 2H), 3.65 (m, 2H), 3.55 (m, 2H), 3.26 (s, IH), 1.70 (s, 6H), 1.69-1.60 (m, 4H), 1.60 (m, IH).
XH NMR (400 MHz, DMSO-d6) δ 8.30 (m, IH), 7.98 (s, IH), 7.92 (m, IH), 7.61 (m, IH), 7.48 (m, IH), 4.48 (m, 2H), 3.25 (s, IH), 1.75 (m, 2H), 1.70 (s, 6H), 1.30-1.28 (m, 4H), 0.84 (m, 3H).
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.91 (m, IH), 7.63 (m, IH), 7.48 (m, IH), 4,50 (m, 2H), 3.65 (m, 2H), 3.55 (m, 2H), 3.26 (s, IH), 1.74 (m, IH), 1.70 (s, 6H), 1.69-1.44 (m, 4H), 1.60 (m, IH).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 2H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, IH), 4.36 (m, 2H), 3.75 (m, 2H), 2.45 (m, 4H), 1.90 (m, 2H), 1.82 (s, 6H), 1.59-1.50(m, 6H).
1H NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.89 (m, IH), 7.72 (m, 2H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, IH), 5.36 (m, 2H), 3.74 (m, 2H), 2.45 (m, 4H), 1.82 (s, 6H), 1.80 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.58 (m, IH), 7.57-7.37 (m, 6H), 7.25 (m, IH), 4.15 (m, 2H), 2.65 (s, 2H), 1.70 (m, 2H), 1.45 (s, 6H), 1.31 (m, 2H), 0.90 (m, 3H).
SGT-238
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.57 (m, IH), 7.45 (m, 2H), 6.28 (s, IH), 4.35 (m, 2H), 1.70 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m. 3H).
*H NMR (400 MHz, DMSO-d6) δ 7.94 (m, IH), 7.67 (s, IH), 7.57 (m, IH), 7.43 (m, 2H), 6.27 (s, IH), 4.25 (m, 2H), 2.53 (m, 6H), 1.72 (m, 2H), 1.69 (m, 4H), 1.65 (s. 6H), 1.31 (m. 4H), 0.90 (m, 3H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.58 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.25 (m, 2H), 3.66 (m, 4H), 2.25 (m, 4H), 1.70 (m, 2H), 1.31 (m, 2H), 0.90 (m, 3H).
lH NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 4.35 (m, 2H), 1.70 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H).
!H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 4.25 (m, 2H), 2.53 (m, 6H), 1.72 (m, 2H), 1.69 (m, 4H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H).
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.25 (m, 2H), 3.66 (m, 4H), 2.25 (m, 4H), 1.70 (m, 2H), 1.31 (m, 2H), 0.90 (m, 3H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.35 (m, 2H), 3.55 (m, 4H), 1.65 (s, 6H), 1.61 (m, IH), 1.48 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.35 (m, 2H), 3.55 (m, 4H), 2.51 (m, 6H), 1.69 (m, 8H), 1.66 (s, 6H), 1.61 (m, IH), 1.48 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.35- 7.27 (m, 7H), 4.35 (m, 2H), 3.55 (m, 8H), 2.23 (m, 4H), 1.61 (m, IH), 1.48 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.58 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.47 (m, 2H), 2.15 (m, 4H), 1.77 (m, 2H), 1.55 (m, 4H), 1.31 (m, 4H), 0.90 (m, 3H)
lH NMR (400 MHz, DMSO-d6) δ 8.22 (s, IH), 7.99 (dd, /=7.0, 1.2Hz, IH), 7.52 (s, IH), 7.49 (dd, =7.0, 1.2Hz, IH), 7.38 (m, IH), 7.34 (m, 2H), 7.12 (m, 2H), 7.06 (m, IH), 4.47 ( 2H), 2.15 (m, 4H), 1.77 (m, 2H), 1.55 (m, 4H), 1.31 (m, 4H). 0.90 (m, 3H)
1H NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.67 (s, IH), 7.59 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.47 (m, 2H), 3.55 (m, 4H), 2.15 (m, 4H), 1.67 (m, 4H), 1.62 (m, IH), 1.55 (m, 4H).
1H NMR (400 MHz, DMSO-d6) δ 7.61 (m, IH), 7.57-7.37 (m, 7H), 7.23 (s, IH), 7.19 (s, IH), 7.12 (m, IH), 4.47 (m, 2H), 1.77 (s, 6H), 1.67 (m, 2H), 1.32 (m, 4H), 0.91 (m, 3H). Solubility of SGT-42
The solubility of SGT-42 was tested in water, dimethyl sulfoxide, and propane- 1,2-diol (propylene glycol) according to British Pharmacopoeia procedures for determining solubility. Approximately 50 mg of SGT-42 was added to each solvent. The results are summarised in Table 4 below.
Table 4.
6.2 Cannabinoid receptor binding affinity
The cannabinoid receptor binding affinity of selected compounds of the invention was evaluated using the following tests.
GPCR functional assay: Human cannabinoid CB1 receptor - agonist effect
This test evaluated the agonist activity of compounds of the invention at the human CB 1 receptor expressed in transfected CHO cells, as determined by measuring their effects on cAMP modulation using the HTRF detection method.
The cells were suspended in HBSS buffer (Invitrogen) complemented with 20 mM HEPES (pH 7.4), then distributed in microplates at a density of 5.103 cells/well in the presence of either of the following: HBSS (basal control), the reference agonist at 30 nM (stimulated control) or various concentrations (EC50 determination), or the test compound.
Thereafter, the adenylyl cyclase activator NKH 477 was added at a final concentration of 3 μΜ.
Following 20 min incubation at 37°C, the cells were lysed and the fluorescence acceptor (D2- labeled cAMP) and fluorescence donor (anti-cAMP antibody labeled with europium cryptate) were added.
After 60 min at room temperature, the fluorescence transfer was measured at ex=337 nm and em=620 and 665 nm using a microplate reader (Rubystar, BMG).
The cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio).
The results are expressed as a percent of the control response to 30 nM CP 55940.
The standard reference agonist was CP 55940, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC50 value was calculated.
Reference: FELDER, C.C., JOYCE, K.E., BRILET, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. and MITCHELL, R.L. (1995), Comparison of the
pharmacology and signal transduction of the human cannabinoid CBi and CB2 receptors, Mol. Pharmacol., 48: 443.
Assay volume and format: 20 μΐ in 96-well plate
Compound addition: [lOOx] solution in solvent then
[lOx] solution in HBSS and 0.1% BSA
Maximum tolerable DMSO concentration: 1%
The results of the tests are summarised in Table 5 below.
GPCR functional assay: Human cannabinoid CB2 receptor - agonist effect
This test evaluated the agonist activity of compounds of the invention at the human CB2 receptor expressed in transfected CHO cells, as determined by measuring their effects on cAMP modulation using the HTRF detection method.
The cells were suspended in HBSS buffer (Invitrogen) complemented with 20 mM HEPES (pH 7.4), then distributed in microplates at a density of 7.5xl03 cells/well in the presence of either of the following: HBSS (basal control), the reference agonist at 100 nM (stimulated control) or various concentrations (EC50 determination), or the test compound.
Thereafter, the adenylyl cyclase activator NKH 477 was added at a final concentration of 3 μΜ.
Following 10 min incubation at 37°C, the cells were lysed and the fluorescence acceptor (D2- labeled cAMP) and fluorescence donor (anti-cAMP antibody labeled with europium cryptate) were added.
After 60 min at room temperature, the fluorescence transfer was measured at
nm and em=620 and 665 nm using a microplate reader (Rubystar, BMG).
The cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio).
The results are expressed as a percent of the control response to 100 nM WIN 55212-2.
The standard reference agonist was WIN 55212-2, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC 50 value was calculated.
Reference: FELDER, C.C., JOYCE, K.E., BRILET, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. and MITCHELL, R.L. (1995), Comparison of the pharmacology and signal transduction of the human cannabinoid CBi and CB2 receptors, Mol. Pharmacol., 48: 443.
Assay volume and format: 20 μΐ in 96-well plate
Compound addition: [lOOx] solution in solvent then
[lOx] solution in HBSS and 0.1% BSA
Maximum tolerable DMSO concentration: 1%
The results of the tests are summarised in Table 5 below.
Table 5.
# EC50 value below the lowest test concentration. Concentration-response curve shows more than 50 % effect at the lowest validated testing concentration.
## EC50 value not calculable. Concentration-response curve shows less than 25% effect at the highest validated testing concentration. 6.3 Off-target G-protein coupled receptor and ligand-gated ion channel screen
Fifteen compounds (SGT-24, SGT-25, SGT-42, SGT-56, SGT-60, SGT-65, SGT-149, SGT- 153, SGT-161, SGT-209, SGT-214, SGT-238, SGT-239, SGT-240 and SGT-247) were tested at ΙμΜ to measure their binding affinity against a panel of 53 common G-protein coupled receptor and ligand-gated ion channel targets, to assess their potential to cause side effects.
The receptors and channels tested against were adenosine Al, A2A and A3, adrenergic al, a2, βΐ and β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2,
cholecystokinin CCK1, dopamine Dl and D2S, endothelin ETA, GABA (non- selective), galanin GAL2, chemokine CXCR2 and CCR1, histamine HI and H2, melatonin MT1, muscarininc Ml, M2 and M3, tachykinin NK2 and NK3, neuropeptide Y Yl and Y2, neurotensin NTS1, opioid μ, δ, κ and NOP, prostaglandin EP4, serotonin 5-HT1A, IB, 2A, 2B, 3, 5A, 6 and 7, somatostatin SST, vasoactive intestinal polypeptide VPAC1, vasopressin VIA, Ca2+ channel L, KV channel, SKCa channel, Na-i- channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter and serotonin transporter. In general, the affinity of the compounds tested at these targets was significantly lower than that recorded against the cannabinoid CB 1 and CB2 receptors.
Only two target - ligand combinations achieved more than 50% displacement of the appropriate reference ligand at ΙμΜ. SGT-153 achieved 53% displacement of IB-MECA from adenosine A3 receptor at ΙμΜ and SGT-60 achieved 60% displacement of diazepam from central benzodiazepine receptor at ΙμΜ.
Some weak affinity was seen against 5-HT1A and MT1 receptors. However, due to their high CB 1 and CB2 affinity, the tested compounds are still generally highly selective for CB 1 and CB2 receptors.
The data in Table 6 shows that the Ki of compounds SGT-24, SGT-25, SGT-42, SGT-60, SGT-65 and SGT-149 is greater than 1000 nM. The data in Table 5 shows that the EC50 for these compounds is less than 1 nM. This suggests that these compounds were over l,000x selective for CB 1 and CB2 receptors over all other receptors and channels tested, and that compound SGT-42 was close to 10,000x selectivite for CB 1 and CB2.
The results of the assay screen for SGT-24, SGT-42, SGT-65 and SGT-149 are provided in Table 6 below (each assay is in bold, followed by the reference radioligand used in that assay).
Most of the compounds were selective for CBl over CB2. SGT-56 the highest selectivity, being 19.7x selective for CB l over CB2.
SGT-214, by contrast was 23.4x selective for CB2 over CB l.
Table 6.
SGT-65 -6 106.2 1.6E-10 4.1E-11 0.9
SGT-149 -6 105.9 1.6E-10 4.1E-11 0.9 alpha 2 (non-selective) (antagonist radioligand) yohimbine
SGT-24 -4 103.5 3.9E-08 1.7E-08 0.8
SGT-42 -14 113.8 3.9E-08 1.7E-08 0.8
SGT-65 -17 116.7 3.9E-08 1.7E-08 0.8
SGT-149 -8 108.0 3.9E-08 1.7E-08 0.8 beta 1 (h) ( agonist
atenolol
radioliganc )
SGT-24 0 99.8 2.3E-07 1.3E-07 0.9
SGT-42 8 92.1 2.3E-07 1.3E-07 0.9
SGT-65 3 97.4 2.3E-07 1.3E-07 0.9
SGT-149 -2 102.3 2.3E-07 1.3E-07 0.9 beta 2 (h) ( agonist
ICI 118551
radioliganc )
SGT-24 -1 100.7 7.2E-10 2.4E-10 1.2
SGT-42 1 98.6 7.2E-10 2.4E-10 1.2
SGT-65 0 100.2 7.2E-10 2.4E-10 1.2
SGT-149 -4 103.8 7.2E-10 2.4E-10 1.2
ATI (h) (ai itagonist
saralasin
radioligant )
SGT-24 -14 113.8 4.5E-10 2.2E-10 0.8
SGT-42 6 94.4 4.5E-10 2.2E-10 0.8
SGT-65 9 90.6 4.5E-10 2.2E-10 0.8
SGT-149 1 98.7 4.5E-10 2.2E-10 0.8
BZD (central) (agonist radioligand) diazepam
SGT-24 -45 144.6 6.5E-09 5.5E-09 0.8
SGT-42 -25 125.1 6.5E-09 5.5E-09 0.8
SGT-65 -42 141.9 6.5E-09 5.5E-09 0.8
SGT-149 -41 140.6 6.5E-09 5.5E-09 0.8
B2 (h) (agonist radioligand) NPC 567
SGT-24 -7 106.7 2.7E-08 1.4E-08 0.8
SGT-42 -3 102.6 2.7E-08 1.4E-08 0.8
SGT-65 -5 104.8 2.7E-08 1.4E-08 0.8
SGT-149 0 100.3 2.7E-08 1.4E-08 0.8
CB1 (h) (agonist radioligand) CP 55940
SGT-24 105 -4.7 6.6E-10 5.8E-10 1.0
SGT-42 100 -0.4 6.6E-10 5.8E-10 1.0
SGT-65 103 -2.5 6.6E-10 5.8E-10 1.0
SGT-149 99 0.8 6.6E-10 5.8E-10 1.0
CCKl (CC £A) (h) (agonist radioligand) CCK-8s
SGT-24 -11 110.7 8.8E-11 6.6E-11 1.4
SGT-42 -9 109.5 8.8E-11 6.6E-11 1.4
SGT-65 2 97.9 8.8E-11 6.6E-11 1.4
SGT-149 -41 141.3 8.8E-11 6.6E-11 1.4
Dl (h) (ant agonist
SCH 23390
radioliganc )
SGT-24 -1 101.4 2.7E-10 l.lE-10 1.2
SGT-42 10 90.1 2.7E-10 l.lE-10 1.2
SGT-65 9 90.9 2.7E-10 l.lE-10 1.2
SGT-149 14 86.1 2.7E-10 l.lE-10 1.2
D2S (h) (ai itagonist
(+)butaclamol
radioliganc )
SGT-24 9 90.8 2.8E-09 9.5E-10 1.1
SGT-42 9 90.9 2.8E-09 9.5E-10 1.1
SGT-65 -4 104.3 2.8E-09 9.5E-10 1.1
SGT-149 13 87.3 2.8E-09 9.5E-10 1.1
ETA (h) (agonist radioligand) endothelin- 1
SGT-24 -3 102.7 3.0E-11 1.5E-11 0.8
SGT-42 8 92.5 3.0E-11 1.5E-11 0.8
SGT-65 -3 102.6 3.0E-11 1.5E-11 0.8
SGT-149 -2 102.4 3.0E-11 1.5E-11 0.8
GABA (non-selective) (agonist radioligand) GABA
SGT-24 -3 103.5 6.7E-08 4.0E-08 1.0
SGT-42 -1 100.9 6.7E-08 4.0E-08 1.0
SGT-65 0 99.5 6.7E-08 4.0E-08 1.0
SGT-149 -12 111.9 6.7E-08 4.0E-08 1.0
GAL2 (h) ( agonist
galanin
radioliganc )
SGT-24 -5 104.8 2.8E-10 2.6E-10 0.9
SGT-42 -5 105.0 2.8E-10 2.6E-10 0.9
SGT-65 -5 104.8 2.8E-10 2.6E-10 0.9
SGT-149 -12 111.5 2.8E-10 2.6E-10 0.9
CXCR2 (IL-8B) (h) (agonist radioligand) IL-8
SGT-24 -14 114.2 2.3E-10 l.lE-10 1.5
SGT-42 -13 113.2 2.3E-10 l.lE-10 1.5
SGT-65 -12 111.9 2.3E-10 l.lE-10 1.5
SGT-149 -1 101.3 2.3E-10 l.lE-10 1.5
CCRl (h) ( agonist
MIP-1 alpha
radioliganc )
SGT-24 -4 104.1 8.3E-11 5.5E-11 1.3
SGT-42 -4 103.7 8.3E-11 5.5E-11 1.3
SGT-65 -14 114.1 8.3E-11 5.5E-11 1.3
SGT-149 -7 107.4 8.3E-11 5.5E-11 1.3
HI (h) (anl agonist
pyrilamine
radioliganc )
SGT-24 -16 115.5 2.4E-09 1.5E-09 1.2
SGT-42 -19 118.6 2.4E-09 1.5E-09 1.2
SGT-65 -5 104.8 2.4E-09 1.5E-09 1.2
SGT-149 -12 111.8 2.4E-09 1.5E-09 1.2
H2 (h) (ant agonist
cimetidine
radioliganc )
SGT-24 0 100.0 4.5E-07 4.3E-07 1.1
SGT-42 -5 104.8 4.5E-07 4.3E-07 1.1
SGT-65 -18 118.2 4.5E-07 4.3E-07 1.1
SGT-149 1 99.4 4.7E-07 4.5E-07 0.7
MTl (MLIA) (h) (agonist radioligand) melatonin
SGT-24 9 91.0 5.5E-10 4.4E-10 0.9
SGT-42 13 86.8 5.5E-10 4.4E-10 0.9
SGT-65 39 60.8 5.5E-10 4.4E-10 0.9
SGT-149 19 80.7 5.5E-10 4.4E-10 0.9
Ml (h) (an tagonist
pirenzepine
radioliganc )
SGT-24 -13 113.5 2.3E-08 2.0E-08 1.1
SGT-42 -20 120.0 2.3E-08 2.0E-08 1.1
SGT-65 -15 115.3 2.3E-08 2.0E-08 1.1
SGT-149 -21 121.4 2.3E-08 2.0E-08 1.1
M2 (h) (an tagonist
methoctramine
radioliganc )
SGT-24 -9 109.5 3.1E-08 2.1E-08 1.1
SGT-42 -5 105.5 3.1E-08 2.1E-08 1.1
SGT-65 -4 104.4 3.1E-08 2.1E-08 1.1
SGT-149 -4 103.8 3.1E-08 2.1E-08 1.1
M3 (h) (an tagonist
4-DAMP
radioliganc )
SGT-24 1 99.3 6.0E-10 4.3E-10 0.9
SGT-42 -2 102.0 6.0E-10 4.3E-10 0.9
SGT-65 0 100.1 6.0E-10 4.3E-10 0.9
SGT-149 -10 110.4 6.0E-10 4.3E-10 0.9
NK2 (h) (a gonist radioligand) [NleulO]-NKA (4-10)
SGT-24 -4 103.9 4.2E-09 2.3E-09 0.8
SGT-42 -7 106.9 4.3E-09 2.3E-09 0.8
SGT-65 10 90.3 4.3E-09 2.3E-09 0.8
SGT-149 4 96.3 4.3E-09 2.3E-09 0.8
NK3 (h) (a ntagonist
SB 222200
radioliganc )
SGT-24 -8 107.8 5.5E-09 2.9E-09 0.8
SGT-42 -4 104.1 5.5E-09 2.9E-09 0.8
SGT-65 -6 106.2 5.5E-09 2.9E-09 0.8
SGT-149 -3 103.5 5.5E-09 2.9E-09 0.8
Yl (h) (agonist radioligand) NPY
SGT-24 -17 117.1 8.4E-11 5.9E-11 1.0
SGT-42 -26 125.9 8.4E-11 5.9E-11 1.0
SGT-65 -12 112.1 8.4E-11 5.9E-11 1.0
SGT-149 -13 113.4 8.4E-11 5.9E-11 1.0
Y2 (h) (agonist radioligand) NPY
SGT-24 1 98.5 2.7E-11 l.lE-11 0.7
SGT-42 6 94.5 2.7E-11 l.lE-11 0.7
SGT-65 12 87.7 2.7E-11 l.lE-11 0.7
SGT-149 15 85.5 2.7E-11 l.lE-11 0.7
NTSl (NTl) (h) (agonist radioligand) neurotensin
SGT-24 -22 122.0 2.5E-10 2.0E-10 0.7
SGT-42 -21 121.3 2.5E-10 2.0E-10 0.7
SGT-65 -28 127.6 2.5E-10 2.0E-10 0.7
SGT-149 -10 109.8 2.5E-10 2.0E-10 0.7 delta 2 (DOP) (h) (agonist radioligand) DPDPE
SGT-24 6 94.4 3.7E-09 2.2E-09 1.1
SGT-42 4 96.4 3.7E-09 2.2E-09 1.1
SGT-65 3 97.5 3.7E-09 2.2E-09 1.1
SGT-149 12 87.5 3.7E-09 2.2E-09 1.1 kappa (KOP) (agonist radioligand) U 50488
SGT-24 -4 103.9 9.4E-10 6.2E-10 1.1
SGT-42 5 95.2 9.4E-10 6.2E-10 1.1
SGT-65 0 99.7 9.4E-10 6.2E-10 1.1
SGT-149 36 64.1 9.4E-10 6.2E-10 1.1 mu (MOP) (h) (agonist radioligand) DAMGO
SGT-24 1 99.0 9.8E-10 4.1E-10 1.1
SGT-42 9 90.6 9.8E-10 4.1E-10 1.1
SGT-65 -4 104.3 9.8E-10 4.1E-10 1.1
SGT-149 -6 105.5 1.1E-09 4.4E-10 0.9
NOP (ORL1) (h) (agonist radio igand) nociceptin
SGT-24 7 93.2 8.7E-10 1.7E-10 1.4
SGT-42 8 91.9 8.7E-10 1.7E-10 1.4
SGT-65 -8 107.7 8.7E-10 1.7E-10 1.4
SGT-149 -6 105.9 8.7E-10 1.7E-10 1.4
EP4 (h) (agonist radioligand) PGE2
SGT-24 10 89.7 4.4E-10 1.7E-10 0.8
SGT-42 2 98.3 4.4E-10 1.7E-10 0.8
SGT-65 4 96.0 4.4E-10 1.7E-10 0.8
SGT-149 4 95.6 4.4E-10 1.7E-10 0.8
5-HT1A (h) (agonist
8-OH-DPAT
radioligant )
SGT-24 15 85.5 6.0E-10 3.7E-10 1.4
SGT-42 23 76.6 6.0E-10 3.7E-10 1.4
SGT-65 6 93.8 6.0E-10 3.7E-10 1.4
SGT-149 12 88.4 6.0E-10 3.7E-10 1.4
5-HT1B (antagonist
serotonin
radioligand)
SGT-24 -6 105.6 6.6E-09 4.1E-09 0.7
SGT-42 -3 103.4 6.6E-09 4.1E-09 0.7
SGT-65 -6 105.8 6.6E-09 4.1E-09 0.7
SGT-149 -9 108.5 6.6E-09 4.1E-09 0.7
5-HT2A (h) (antagonist radioligand) ketanserin
SGT-24 1 99.2 1.3E-09 6.9E-10 1.1
SGT-42 2 98.3 1.3E-09 6.9E-10 1.1
SGT-65 -4 103.8 1.3E-09 6.9E-10 1.1
SGT-149 9 90.5 1.3E-09 6.9E-10 1.1
5-HT2B (h) (agonist (±)D0I
radioliganc )
SGT-24 -8 107.6 2.5E-09 1.2E-09 1.0
SGT-42 -18 117.8 2.5E-09 1.2E-09 1.0
SGT-65 4 95.6 2.5E-09 1.2E-09 1.0
SGT-149 11 88.5 2.5E-09 1.2E-09 1.0
5-HT3 (h) (antagonist radioligand) MDL 72222
SGT-24 1 99.0 1.4E-08 9.6E-09 1.2
SGT-42 -6 105.9 1.4E-08 9.6E-09 1.2
SGT-65 -3 103.0 1.4E-08 9.6E-09 1.2
SGT-149 -1 100.9 1.4E-08 9.6E-09 1.2
5-HT5a (h) (agonist
. serotonin
radioliganc )
SGT-24 -3 103.0 1.6E-07 8.0E-08 0.8
SGT-42 -1 101.2 1.6E-07 8.0E-08 0.8
SGT-65 1 99.4 1.6E-07 8.0E-08 0.8
SGT-149 -11 110.6 1.6E-07 8.0E-08 0.8
5-HT6 (h) (agonist
serotonin
radioligant )
SGT-24 -9 108.7 9.4E-08 4.5E-08 0.9
SGT-42 -3 103.3 9.4E-08 4.5E-08 0.9
SGT-65 -5 104.5 9.4E-08 4.5E-08 0.9
SGT-149 -4 104.1 9.4E-08 4.5E-08 0.9
5-HT7 (h) agonist
" serotonin
radioligant )
SGT-24 5 95.5 4.5E-10 1.6E-10 1.1
SGT-42 7 93.0 4.5E-10 1.6E-10 1.1
SGT-65 -13 113.1 4.5E-10 1.6E-10 1.1
SGT-149 2 97.7 4.5E-10 1.6E-10 1.1
. , . .. . , . . ,. somatostatin- sst (non-selective) (agonist radioligand) ^
SGT-24 -8 108.1 3.4E-10 2.1E-10 1.0
SGT-42 -11 110.5 3.4E-10 2.1E-10 1.0
SGT-65 -25 124.8 3.4E-10 2.1E-10 1.0
SGT-149 -26 125.7 3.4E-10 2.1E-10 1.0
VPACl (VIPl) (h) (agonist radioligand) VIP
SGT-24 -2 102.3 2.4E-10 1.3E-10 0.9
SGT-42 -3 103.4 2.4E-10 1.3E-10 0.9
SGT-65 -1 101.2 2.4E-10 1.3E-10 0.9
SGT-149 -5 104.9 2.4E-10 1.3E-10 0.9
[d(CH2)51,Tyr( Me)2]-
Via (h) (agonist radioligand)
AVP
SGT-24 -4 104.2 7.6E-10 4.8E-10 0.9
SGT-42 5 94.5 7.6E-10 4.8E-10 0.9
SGT-65 1 98.5 7.6E-10 4.8E-10 0.9
SGT-149 -4 104.4 7.6E-10 4.8E-10 0.9
Ca2+ channel (L, verapamil site)
D 600
(phenylalkylamine) (antagonist radioligand)
SGT-24 -8 108.5 1.4E-08 7.0E-09 0.5
SGT-42 -4 103.8 1.4E-08 7.0E-09 0.5
SGT-65 -12 111.8 1.4E-08 7.0E-09 0.5
SGT-149 -7 107.5 1.4E-08 7.0E-09 0.5
KV channe (antagonist radioligand) alpha -dendrotoxin
SGT-24 -15 115.1 2.0E-10 1.6E-10 0.9
SGT-42 -12 111.8 2.0E-10 1.6E-10 0.9
SGT-65 -9 108.7 2.0E-10 1.6E-10 0.9
SGT-149 -4 104.1 2.0E-10 1.6E-10 0.9
SKCa channel (antagonist radioligand) apamin
SGT-24 1 99.2 8.5E-12 4.3E-12 0.8
SGT-42 -15 114.8 8.5E-12 4.3E-12 0.8
SGT-65 5 94.9 8.5E-12 4.3E-12 0.8
SGT-149 1 99.2 8.5E-12 4.3E-12 0.8
Na+ channel (site 2) (antagonist radioligand) veratridine
SGT-24 -8 108.1 8.6E-06 7.7E-06 1.3
SGT-42 6 94.4 8.6E-06 7.7E-06 1.3
SGT-65 -10 110.2 8.6E-06 7.7E-06 1.3
SGT-149 1 98.9 8.6E-06 7.7E-06 1.3
CI- channel (GABA-gated) (antagonist
picrotoxinin
radioliganc )
SGT-24 45 55.1 1.4E-07 1.2E-07 0.8
SGT-42 4 96.5 1.4E-07 1.2E-07 0.8
SGT-65 47 53.3 1.4E-07 1.2E-07 0.8
SGT-149 28 71.5 1.4E-07 1.2E-07 0.8 norepineph rine transporter (h) (antagonist
protriptyline
radioligant )
SGT-24 0 99.9 3.1E-09 2.3E-09 1.0
SGT-42 -7 107.0 3.1E-09 2.3E-09 1.0
SGT-65 -4 104.4 3.1E-09 2.3E-09 1.0
SGT-149 -1 100.8 3.1E-09 2.3E-09 1.0 dopamine transporter (h) (antagonist
BTCP
radioligand)
SGT-24 -6 105.7 9.7E-09 5.1E-09 1.1
SGT-42 -11 110.6 9.7E-09 5.1E-09 1.1
SGT-65 -1 100.6 9.7E-09 5.1E-09 1.1
SGT-149 12 88.5 9.7E-09 5.1E-09 1.1
5-HT trans jorter (h) (antagonist radioligand) imipramine
SGT-24 -7 107.5 1.9E-09 8.9E-10 0.8
SGT-42 -7 107.0 1.9E-09 8.9E-10 0.8
SGT-65 -8 108.4 1.9E-09 8.9E-10 0.8
SGT-149 3 97.1 1.9E-09 8.9E-10 0.8
6.4 Pharmaceutical compositions
Pharmaceutical compositions of the invention were prepared by dissolving a compound of the invention in a solvent, such as diethyl ether or acetone or a mixture thereof, and mixing the solution with a suitable carrier. The solvent was removed and the mixture divided up into gel caps (capsules) in equal portions so that each gel cap contained a known dose of the compound of the invention. SGT-24 with mannitol (capsule 1)
Gel caps containing 4 mg of SGT-24 and -196 mg mannitol as carrier were prepared as described above. 40 mg of SGT-42 was dissolved in 20 ml of diethyl ether and 1960 mg of mannitol. The mixture was dried and 200 mg of the mixture was placed in each gel cap. SGT-24 with MSM (capsule 2)
Gel caps containing 4 mg of SGT-24 and ~ 196 mg methylsulfonylmethane (MSM) as carrier were prepared as described above. 40 mg of SGT-42 was dissolved in 20 ml of diethyl ether (or 20 ml of 2: 1 diethyl ether: acetone) and 1960 mg of MSM. The mixture was dried and 200 mg of the mixture was placed in each gel cap.
SGT-42 with MSM (capsule 3)
Gel caps containing 5 mg of SGT-42 and ~ 196 mg methylsulfonylmethane (MSM) as carrier were prepared as described above. 50 mg of SGT-42 was dissolved in 20 ml of diethyl ether and 1950 mg of MSM. The mixture was dried and 200 mg of the mixture was placed in each gel cap.
6.5 E-liquid composition
E-liquid compositions of the invention for use in e-cigarettes were prepared by dissolving a compound of the invention in a solvent, such as propylene glycol, glycerine, and optionally a surfactant with stirring. Optionally, a flavour enhancer may also be added. The composition may also be filtered before use.
SGT-42 e-liquid composition (E-liquid 1)
An e-liquid containing 350mg of SGT-42 was prepared with 10 ml propylene glycol, 3 ml vegetable glycerin, 2 drops of Tween 20, and 10 drops of Tasty Puff flavour enhancer were prepared as described above. The mixture was filtered through glass wool and was then used to fill 2 ml e-cigarette cartridges.
SGT-42 tablets
A batch of tablets containing SGT-42, beta cyclodextrin, microcrystalline cellulose, magnesium stearate, and magnesium silicate in tablet form was produced as described below. The content of each component by weight is listed in Table 7.
Table 7.
The cyclodextrin was weighed and placed in a ribbon blender. The SGT-42 active was weighed and fine sieved in to the ribbon blender. The ingredients were then blended for ten minutes.
The Microcrystallme Cellulose, Magnesium Silicate, and Crosscarmellose Sodium were then weighed, added to the blender, and the mixture was blended for a further ten minutes.
Finally, the Magnesium Sterate was weighed, added to the mix, and blended for 5 minutes. The blended mixture of ingredients was then tabletted. 6.6 Use of cannabinoid compounds of the invention Capsule 1
One volunteer initially took one "capsule 1" orally.
Effects were first observed after approximately 180 minutes. The volunteer experienced strong cannabinomimetic effects. The test was not continued beyond 180 minutes.
Capsule 2
Six volunteers were breath tested to ensure they had not consumed alcohol. The volunteers were each fed a three course meal before commencement of the test. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test.
One "capsule 2" was provided per volunteer, which was swallowed. The volunteers were asked questions every 60 minutes regarding how they were feeling and what effects they were observing.
Surprisingly, effects were first observed after approximately 20-60 minutes (when compared to 180 minutes when mannitol was used as carrier). All volunteers experienced strong cannabinomimetic effects, were relaxed, and reported a positive mood change. After a further 60 minutes, all volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood.
The test concluded after a further 60 minutes (180 minutes in total). The cannabinomimetic effects persisted after the test concluded.
After approximately 90 minutes, all volunteers reported experiencing voracious hunger.
None of the volunteers experienced a significant increase in blood pressure and only one volunteer experienced a significant increase in heart rate.
Capsule 3
Four volunteers were breath tested to ensure they had not consumed alcohol. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test.
One "capsule 3" was provided per volunteer, which was swallowed. The volunteers were asked questions every 30 minutes regarding how they were feeling and what effects they were observing.
Surprisingly, effects were first observed after approximately 30 minutes (when compared to 180 minutes when mannitol was used as carrier). All volunteers experienced strong cannabinomimetic effects, were relaxed, and reported a positive mood change.
After 60 minutes, three volunteers were provided with a second "capsule 3", which was swallowed. All three volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood. After 110 minutes, two of the volunteers were provided with a third "capsule 3", which was swallowed. Both volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood.
The test concluded after 180 minutes. The cannabinomimetic effects persisted after the test concluded.
After approximately 100 minutes, all volunteers reported experiencing voracious hunger.
None of the volunteers experienced a significant increase in blood pressure and only one volunteer experienced a significant increase in heart rate.
E-liquid 1
Five volunteers were breath tested to ensure they had not consumed alcohol. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test.
Each volunteer was allowed to inhale two puffs of e-liquid from an e-cigarette. The volunteers were asked questions every 30 minutes regarding how they were feeling and what effects they were observing.
Effects were first observed after approximately 1-2 minutes. All volunteers experienced mild to moderate cannabinomimetic effects, were relaxed, and reported a positive mood change.
After 30 minutes most volunteers reported that the cannabinomimetic effects were diminishing, but two volunteers reported feeling cannabinomimetic effects for up to 60 minutes.
At 60 minutes the volunteers were allowed to inhale two further puffs of e-liquid from an e- cigarette. Most volunteers inhaled three or four puffs of e-liquid from the e-cigarette. All volunteers reported moderate cannabinomimetic effects at three puffs and strong
cannabinomimetic effects after four puffs.
All volunteers reported cannabinomimetic effects diminishing after approximately 40 minutes after inhalation and all volunteers reported feeling no cannabinomimetic effects after 90 minutes after inhalation.
All volunteers reported feeling more relaxed and had an increased positive mood. All volunteers reported experiencing voracious hunger. It is not the intention to limit the scope of the invention to the abovementioned examples only. As would be appreciated by a skilled person in the art, many variations are possible without departing from the scope of the invention.
7. INDUSTRIAL APPLICATION The compounds of the invention described herein have central nervous system activity and can, therefore, be used to treat a variety of diseases or conditions. The compounds are especially useful treating pain, treating nausea and/or emesis, stimulating appetite, inducing a
euphoric effect, inducing relaxation, and inducing a positive mood change, in particular for treating pain, treating nausea and/or emesis, and stimulating appetite.
Claims
1. A compound of formula I,
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and R121) are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein
each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof. 2. The compound of claim 1, wherein
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cs haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted.
3. The compound of claim 1 , wherein R6a and R6 together form 3 to 7 membered heterocycle.
4. The compound of claim 1 wherein R6c is cyano.
5. The compound of any one of claims 1 to 4, wherein Y is selected from CH2CH2, CH2S, CH20, SO2CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2,
(C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH.
6. The compound of any one of claims 1 to 4, wherein Y is selected from CH2CH2, CH2S, CH20, SO2CH2, S020, SO2NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0),
CH2(C=0), or NH(C=0).
7. The compound of any one of claims 1 to 4, wherein Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0).
8. The compound of any one of claims 1 to 4, wherein Y is selected from (C=0)0 or (C=0)NH.
The compound of any one of claims 1 to 4, wherein Y is (C=0)NH.
10. The compound of any one of claims 1 to 9, wherein R2- 5 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b,
CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, C6-Ci2 aryl, C3- C12 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. 11. The compound of any one of claims 1 to 10, wherein R2-R5 are each independently selected from hydrogen or halo.
12. The compound of any one of claims 1 to 11, wherein Rec is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Q-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Q-Cg alkyl, or C3-C8 heterocycle.
13. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-C8 alkyl, C2-Q alkenyl, C2-Q alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, or C6-Ci2
heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
14. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-Cg alkylene heterocyclyl, C2-Cs alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO,
-N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - 0S(=0)20R, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, -P(=0)(0R)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
15. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-Cs alkylene heterocyclyl, C2-Cg alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
16. The compound of any one of claims 1 to 12, wherein R^c is selected from Ci-C§ alkylene heterocyclyl, C2-Cg alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
A compound of formula la,
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-Cg cycloalkyl ring or 3 to 7 membered heterocyclyl ring; and
Ri2a and Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
18. The compound of claim 17, wherein R6a and R6b are each independently selected from Ci-Cs alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring.
19. The compound of claim 17, wherein R6a and R6b together form 3 to 7 membered heterocycle.
20. The compound of any one of claims 17 to 19, wherein Yi is selected from O, S, or S02.
21. The compound of any one of claims 17 to 20, wherein Yi is O.
22. The compound of any one of claims 17 to 21, wherein Y2 is selected from CH2, O, or NH.
23. The compound of any one of claims 17 to 22, wherein Y2 is selected from NH or O.
24. The compound of any one of claims 17 to 23, wherein Y2 is NH.
25. The compound of any one of claims 17 to 24, wherein R2-R5 and R7-Rnare each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2h,
S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, C6-Ci2 aryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-C12 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
26. The compound of any one of claims 17 to 24, wherein R2-R5 and R7-R11 are each independently selected from hydrogen or halo.
27. The compound of any one of claims 1 to 26, wherein B is CH.
28. The compound of any one of claims 1 to 26, wherein B is N.
29. The compound of any one of claims 1 to 28, wherein Ri2a and Ri2b are each
independently selected from hydrogen, Ci-C8 alkyl, or C6-Ci2 aryl, wherein each of said alkyl
or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, - +R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-C12 aryl Ci-Cs alkyl, or C3-C8 heterocycle. 30. The compound of any one of claims 1 to 29, wherein R12a and R12b are each independently selected from hydrogen, C1-C8 alkyl, or C6-C12 aryl.
31. The compound of any one of claims 1 to 30, wherein R2 is hydrogen, OH, N02, CHO, S02, S03H, NR12aR12b, S02NR12aR12b, CONR12aR12b, halo, d-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C12 aryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR.
32. The compound of any one of claims 1 to 31, wherein R2 is hydrogen or halo.
33. The compound of any one of claims 1 to 32, wherein Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ct-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C12 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -
P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged Cg-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
34. The compound of any one of claims 1 to 33, wherein Ri is selected from CONRi2aRi2t>, CORi2a, COORi2a, Q-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q-Cg fluoroalkyl, Q-Cg bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
35. The compound of any one of claims 1 to 33, wherein Ri is selected from Q-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NO2, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
36. The compound of any one of claims 1 to 33, wherein Ri is selected from Ci-C8 alkyl, CpCs bromoalkyl, Ci-C8 fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -OCN, -SCN, -N=C=0, -NO2, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
37. The compound of any one of claims 1 to 33, wherein Ri is selected from Ci-C8 alkyl, Ci-Cs bromoalkyl, Ci-C8 fluoroalkyl, Ci-C8 cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-Cg alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-Ci2 aryl, Ci-C6 alkylene- C6-Ci2 fluoroaryl,
Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci-
Cg alkyl, C3-C12 cycloalkyl.
38. The compound of any one of claims 1 to 33, wherein Ri is selected from 1 -butyl, 1- pentyl, 5-fluoro-l-pentyl, 4-cyano-l -butyl, 3,3-dimethyl-l-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro-l -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4-tetrahydropyranyl,
methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), l-ethylene-2-(N-mo holinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N-piperidinyl).
39. The compound of any one of claims 1 to 33, wherein RI is selected from 1 -butyl, 1- pentyl, 5-fluoro-l-pentyl, methylene cyclohexyl, methylene-3,3-difluoro-l -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-piperidinyl,
methylene-cycloheptanyl, methylene- 2-bicyclo[2.2.1]heptanyl, and methylene-4- tetrahydropyranyl.
40. The compound of any one of claims 1 to 39, wherein R6a and !½, are each
independently selected from CpC4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl rinj or a 3 to 7 membered heterocyclyl ring.
41. The compound of any one of claims 1 to 40, wherein R6a and R6b are each
independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring.
42. The compound of any one of claims 1 to 41, wherein R6a and R6b are each methyl or R6a and Rg together form a cyclopropyl or cyclopentyl ring.
43. The compound of any one of claims 1 to 40, wherein R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
44. The compound of claim 43, wherein R6a and R6b together form a 4,4-tetrahydropyranyl ring. 45. The compound of any one of claims 1 to 44, wherein the EC50 of the compound of the invention in a CBi and/or CB2 receptor affinity assay is less than about 50 μΜ.
46. The compound of any one of claims 1 to 45, wherein the compound has an inhibition of control specific binding of less than about 65% and/or a control specific binding of at least 40% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GAB A (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS 1, opioid μ, opioid δ, opioid K, opioid NOP, prostaglandin EP4, serotonin 5-HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPACl, vasopressin VIA, Ca2+ channel
L, KV channel, SKCa channel, Na+ channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter.
47. A pharmaceutical composition comprising a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
48. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in treating pain in a subject.
49. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in treating nausea and/or emesis in a subject.
50. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in stimulating appetite in a subject.
51. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in inducing a euphoric effect in a subject.
52. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in relaxing a subject.
53. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in inducing a positive mood change in a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361810968P | 2013-04-11 | 2013-04-11 | |
US61/810,968 | 2013-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014167530A1 true WO2014167530A1 (en) | 2014-10-16 |
Family
ID=51689019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/060636 WO2014167530A1 (en) | 2013-04-11 | 2014-04-11 | Cannabinoid compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014167530A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
WO2020077462A1 (en) | 2018-10-19 | 2020-04-23 | Top Canada Pharmaceuticals Inc. | Powdered botanical extract preparations and formulations thereof |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
CN112375027A (en) * | 2020-12-07 | 2021-02-19 | 中国药科大学 | Indolesulfonamide derivative and medical application thereof |
WO2021155227A1 (en) * | 2020-01-30 | 2021-08-05 | Rti International, Inc. | Indazole derivatives as cannabanoid receptor partial agonists |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
CN116438162A (en) * | 2020-09-17 | 2023-07-14 | 伊赛恩特制药公司 | Modulators of MAS-related G protein receptor X4 and related products and methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999028297A1 (en) * | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma Kg | Substituted indoles, having a thrombin inhibiting effect |
-
2014
- 2014-04-11 WO PCT/IB2014/060636 patent/WO2014167530A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999028297A1 (en) * | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma Kg | Substituted indoles, having a thrombin inhibiting effect |
Non-Patent Citations (3)
Title |
---|
BIECHY, A AND ZARD, S. Z: "A Flexible, Convergent Approach to Polycyclic Indole Structures: Formal Synthesis of (±)-Mersicarpine", ORGANIC LETTERS, vol. 11, no. 13, 2009, pages 2800 - 2803 * |
DATABASE CAPLUS 1999, accession no. 999:375527 * |
DATABASE CAPLUS 2009, accession no. 009:666523 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10638792B2 (en) | 2013-03-15 | 2020-05-05 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
US10117466B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10070669B2 (en) | 2013-12-23 | 2018-09-11 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US11752283B2 (en) | 2013-12-23 | 2023-09-12 | Juul Labs, Inc. | Vaporization device systems and methods |
US10117465B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058124B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10667560B2 (en) | 2013-12-23 | 2020-06-02 | Juul Labs, Inc. | Vaporizer apparatus |
US10201190B2 (en) | 2013-12-23 | 2019-02-12 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10912331B2 (en) | 2013-12-23 | 2021-02-09 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10264823B2 (en) | 2013-12-23 | 2019-04-23 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10701975B2 (en) | 2013-12-23 | 2020-07-07 | Juul Labs, Inc. | Vaporization device systems and methods |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD929036S1 (en) | 2016-06-16 | 2021-08-24 | Pax Labs, Inc. | Vaporizer cartridge and device assembly |
USD913583S1 (en) | 2016-06-16 | 2021-03-16 | Pax Labs, Inc. | Vaporizer device |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
EP3866823A4 (en) * | 2018-10-19 | 2022-11-09 | Fong, Sonny | POWDERED PLANT EXTRACT PREPARATIONS AND FORMULATIONS THEREOF |
WO2020077462A1 (en) | 2018-10-19 | 2020-04-23 | Top Canada Pharmaceuticals Inc. | Powdered botanical extract preparations and formulations thereof |
WO2021155227A1 (en) * | 2020-01-30 | 2021-08-05 | Rti International, Inc. | Indazole derivatives as cannabanoid receptor partial agonists |
EP4097088A4 (en) * | 2020-01-30 | 2024-01-24 | Research Triangle Institute | Indazole derivatives as cannabanoid receptor partial agonists |
CN116438162A (en) * | 2020-09-17 | 2023-07-14 | 伊赛恩特制药公司 | Modulators of MAS-related G protein receptor X4 and related products and methods |
EP4213839A4 (en) * | 2020-09-17 | 2024-08-07 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x4 and related products and methods |
CN112375027A (en) * | 2020-12-07 | 2021-02-19 | 中国药科大学 | Indolesulfonamide derivative and medical application thereof |
CN112375027B (en) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | Indolesulfonamide derivative and medical application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014167530A1 (en) | Cannabinoid compounds | |
JP7644517B2 (en) | KRAS Mutant Protein Inhibitors | |
AU2003220384B2 (en) | Combination treatments for chemokine-mediated diseases | |
CN111848616B (en) | Pyridone derivative and application thereof in preparation of anti-influenza virus medicines | |
AU2015365587B2 (en) | Fused ring heteroaryl compounds and their use as TRK inhibitors | |
ES2331153T3 (en) | N-SULFONYLAMINOFENILETIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS. | |
KR20060072142A (en) | CrF antagonists and bicyclic heterocyclic compounds | |
CN109153687A (en) | Compound of the one kind containing tricyclic heteroaryl | |
JP7245918B2 (en) | Sarsasapogenin structure-based derivative, pharmaceutical composition and use thereof | |
JP6966425B2 (en) | Heterocyclic limited tricyclic sulfonamides as anti-cancer agents | |
JP2007514746A (en) | Thiadiazole as CXC-chemokine receptor ligand and CC-chemokine receptor ligand | |
WO2008134036A1 (en) | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | |
TW201726678A (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
CN112125911A (en) | CDK9 inhibitor and preparation method and application thereof | |
CN111303147B (en) | Pyridone derivatives, compositions thereof and use as anti-influenza virus medicaments | |
JP2024545189A (en) | Tricyclic fused heterocyclic PDE3/4 dual inhibitors and their uses | |
JP2020520960A (en) | Azaaryl derivative, its production method and pharmaceutical application | |
WO2021052501A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
CN101198606A (en) | α-(aryl- or heteroaryl-methyl-)-β-piperidinopropionamide compounds as ORL1-receptor antagonists | |
KR20170117407A (en) | Compound having antitumor activity | |
CN113045569B (en) | Compounds as RET kinase inhibitors and their applications | |
CN112574212B (en) | Pyrimido five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof | |
AU2014365915B2 (en) | Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors | |
RU2534804C1 (en) | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRIDINES, DEMONSTRATING PROPERTIES OF ANTAGONISTS OF ADENOSINE A2A RECEPTORS, AND THEIR APPLICATION | |
MX2007016215A (en) | Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14782376 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14782376 Country of ref document: EP Kind code of ref document: A1 |